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Abstract

There are an estimated 2.5 million people in the United States of America suffering from opioid use disorders.
Of the 2.5 million Americans impacted by opioid use disorders, over half are women. One of the most
challenging aspects of opioid use disorders occurs in the context of pregnancy. Discourse surrounding the
topic of addiction often identifies the root cause of addiction as a moral failing, rather than a
pathophysiological disease. This stigma is amplified in the context of pregnancy and perpetuates the false,
discriminatory notion that pregnant women with opioid use disorders are knowingly “harming” their babies
without regard.
Instead of receiving support, education, and encouragement, pregnant women with opioid use disorders are
faced with stigma, judgment, shame, and guilt. These negative interactions ultimately serve as barriers that
interfere with the ability for early attachment bond development, a monumentally important piece of
newborn development and the most significant contributor to healthy attachment development. These
avoidable, institutionally created barriers propagate both short- and long-term risk factors for the mother and
infant, both independently and as a dyad.
This dissertation will systematically explore several aspects of perinatal opioid use disorders to develop an
evidence-informed practice model for healthcare providers working with pregnant and postpartum women
with opioid use disorders. This dissertation will also explore the intersection of perinatal opioid use disorders
and attachment theory, which will serve as the framework for the PARTNER model, an attachment-based
practice model for providers working with mothers and infants impacted by perinatal opioid use disorders.
Composite case vignettes, informed by clinical experience and empirical literature, are integrated throughout
this dissertation to illuminate and connect the critical concepts that set the foundation for the PARTNER
model.
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ABSTRACT
There are an estimated 2.5 million people in the United States of America suffering
from opioid use disorders. Of the 2.5 million Americans impacted by opioid use disorders,
over half are women. One of the most challenging aspects of opioid use disorders occurs in
the context of pregnancy. Discourse surrounding the topic of addiction often identifies the
root cause of addiction as a moral failing, rather than a pathophysiological disease. This
stigma is amplified in the context of pregnancy and perpetuates the false, discriminatory
notion that pregnant women with opioid use disorders are knowingly “harming” their babies
without regard.
Instead of receiving support, education, and encouragement, pregnant women with
opioid use disorders are faced with stigma, judgment, shame, and guilt. These negative
interactions ultimately serve as barriers that interfere with the ability for early attachment
bond development, a monumentally important piece of newborn development and the most
significant contributor to healthy attachment development. These avoidable, institutionally
created barriers propagate both short- and long-term risk factors for the mother and infant,
both independently and as a dyad.
This dissertation will systematically explore several aspects of perinatal opioid use
disorders to develop an evidence-informed practice model for healthcare providers working
with pregnant and postpartum women with opioid use disorders. This dissertation will also
explore the intersection of perinatal opioid use disorders and attachment theory, which will
serve as the framework for the PARTNER model, an attachment-based practice model for
providers working with mothers and infants impacted by perinatal opioid use disorders.
Composite case vignettes, informed by clinical experience and empirical literature, are
integrated throughout this dissertation to illuminate and connect the critical concepts that
set the foundation for the PARTNER model.
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CHAPTER I: STATEMENT OF THE PROBLEM
THE PERINATAL OPIOID EPIDEMIC
INTRODUCTION, BACKGROUND, AND SIGNIFICANCE
There are an estimated 2.5 million people in the United States of America suffering
from opioid use disorders. Drug overdoses are the leading cause of injury death in the
United States. According to the Centers for Disease Control and Prevention, an average of
115 people die from an opioid overdose on a daily basis (Centers for Disease Control and
Prevention, 2018). Of the 2.5 million Americans impacted by opioid use disorders, over half
are women. Furthermore, women are statistically at higher risk for experiencing the
biopsychosocial risk factors that contribute to opioid dependency and addiction (AitDaoud, Blevins, Khanna, Sharma, & Holstege, 2017). Over the past 20 years, incidence of
opioid overdose amongst women has increased by 400%, in comparison to an increase of
265% amongst their male counterparts (Centers for Disease Control and Prevention,
2018).
One of the most challenging aspects of opioid use disorders occurs in the context of
pregnancy. In 2012, a baby with intrauterine opioid exposure was born every 25 minutes.
This adds up to an estimated 21,732 babies in one year (Patrick, Davis, Lehman, & Cooper,
2015). This number increased fivefold between 2000 and 2012 and the rates have
continued to rise. More than 50 percent of babies born to women who are opioid
dependent are diagnosed with and treated for neonatal abstinence syndrome (NAS), a
temporary postnatal syndrome characterized by chemical dependency and withdrawal
symptoms in infants with intrauterine exposure to certain substances, including opiates
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(Galanter, Kleber, & Brady, 2015; Gomella, Cunningham, & Eyal, 2013; Sanlorenzo, Stark, &
Patrick, 2018).
The statistical prevalence of perinatal opioid use disorders and NAS is certainly
staggering and deserving of societal attention. However, the discourse surrounding these
sensitive health issues is less focused on finding a solution and more interested in the
shock value of “addicted pregnant women” and their “addicted babies,” a paradigm that
only perpetuates stigma and contributes to the problem itself. Decades of research has
consistently identified stigma as a significant, problematic component of the rhetoric of
opioid use disorders, and addiction in general (Cleveland & Gill, 2013; Cleveland & Bonugli,
2014; Cleveland, Bonugli, & McGlothen, 2016; Dimirci, Bogen, & Klionsky, 2015, Holbrook,
2015; Holbrook & Nguyen, 2015; Howard, 2015; Howard, 2016; Jones et al., 2008;
Mattocks, Clark, & Weinreb, 2017; Stengel, 2014; Stone, 2015; Suchman & Luthar, 2000).
Discourse surrounding the topic of addiction often identifies the root cause of
addiction as a moral failing, rather than a pathophysiological disease (Ahern, Stuber, &
Galea, 2006; Corrigan, 2004; Fraser, Barnes, Biggs, & Kain, 2017; Goffman, 1963; Kelly,
Saitz, & Wakeman, 2016; Lloyd, 2013; Major & O’Brien, 2005, Racine, Sattler, & Escande,
2017). This stigma is amplified in the context of pregnancy and perpetuates the false,
discriminatory notion that pregnant women with opioid use disorders are knowingly
“harming” their babies without regard. Sensationalist language further compounds this
stigma. Babies diagnosed with NAS are frequently referred to as “addicted babies” within
mainstream media. In reality, babies diagnosed with NAS are not “addicted” (Cleveland,
2013; Cleveland & Bonugli, 2014; Cleveland et al., 2016; Dimirci et al., 2015; Holbrook,
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2015; Holbrook & Nguyen, 2015; Howard, 2015; Howard, 2016; Jones et al., 2008; Mattocks
et al., 2017; Stengel, 2014; Stone, 2015; Suchman & Luthar, 2000).
These infants experience a physical dependence to the opiate and are treated
immediately upon diagnosis within an appropriate hospital setting, as described by the
National Library of Medicine. However, suggesting that the infant is “addicted” implies
behavioral aspects of addiction disorders that infants simply cannot have developed in the
first few weeks of life (Galanter et al., 2015). NAS is a treatable, temporary syndrome
(Galanter et al., 2015; Gomella et al., 2013; Sanlorenzo et al., 2018). There is a colossal
stigma attached to giving birth to an infant with NAS despite this scientific, evidence-based
information. Ultimately, those who most suffer from this social stigma are the mother and
infant themselves. Stigma is barrier to the development of early attachment bonding, an
vital aspect of early childhood development that impacts how relationships are formed
across the lifespan (Cleveland, 2013; Cleveland & Bonugli, 2014; Cleveland et al., 2016;
Holbrook, 2015; Holbrook & Nguyen, 2015; Howard, 2015; Howard, 2016; Jones et al.,
2008; Stengel, 2014; Stone, 2015; Thigpen & Melton, 2014).
The problematic terminology described above may seem like a simple difference in
semantics and undeserving of reevaluation. This misconception, however, vastly
undermines the power and influence of language choice, perception, and social stigma
(Goodyear-Smith & Buetow, 2001). Empirical research has revealed that women with
perinatal opioid use disorders feel judged, stigmatized, embarrassed, and anxious when
visiting their babies at the hospital. Common triggers include shaming verbal and
nonverbal language of healthcare staff, subjective NAS scoring, and the exclusion of the
mother from participating in the treatment plan for both herself and for her baby. Instead
9

of receiving support, education, and encouragement, they are faced with judgment,
coldness, and indifference (Cleveland, 2013; Cleveland & Bonugli, 2014; Cleveland et al.,
2016; Dimirci et al., 2015; Holbrook, 2015; Holbrook & Nguyen, 2015; Howard, 2015;
Howard, 2016; Jones et al., 2008; Mattocks et al., 2017; Stengel, 2014; Stone, 2015;
Suchman & Luthar, 2000).
As a result, these mothers often avoid prenatal care, communication with healthcare
providers, and visitation in order to circumvent judgment and stigmatization. This
decreases access to medical care, treatment, and the ability to bond with their babies, and
unfortunately can serve to affirm the negative perceptions of some healthcare providers.
These negative consequences also interfere with the ability for early attachment bond
development, a monumentally important piece of newborn development and the most
significant contributor to healthy attachment development. Early attachment bonding
creates a pathway for the way in which individuals engage in human relationships across
the lifespan. These avoidable, institutionally created barriers propagate both short- and
long-term risk factors for the mother and infant, both independently and as a dyad
(Cleveland, 2013; Cleveland & Bonugli, 2014; Cleveland et al., 2016; Dimirci et al., 2015;
Holbrook, 2015; Holbrook & Nguyen, 2015; Howard, 2015; Howard, 2016; Jones et al.,
2008; Mattocks et al., 2017; Stengel, 2014; Stone, 2015; Suchman et al., 2000; Thigpen &
Melton, 2014).
Healthcare providers across the country are unknowingly doing harm to both the
mother and the baby by creating barriers to the development of attachment instead of
fostering connections. There is an extraordinarily strong relationship between traumatic
childhood experiences (physical, sexual, and emotional abuse and/or neglect) and
10

substance use disorders. With this information, it becomes abundantly clear that mothers
in this position are already predisposed to barriers to healthy attachment development
(Felitti et al., 1998; Galanter et al., 2015; Khoury, Tang, Bradley, Cubells, & Ressler, 2010;
Torchalla, Linden, Aube, Strehlau, Neilson, & Krausz, 2014; Wilson, 2015). By diminishing
the opportunity to provide education and foster healthy attachments between these
mothers and their infants, providers are simultaneously, and drastically, increasing risk of
harm and perpetuating this cycle. Fortunately, this problem is both changeable and
preventable with utilization of evidence-based practices applied to this specific population.
The literature that exists has identified and described these barriers to care, and
simultaneously provides recommendations for perinatal opioid use disorders and NAS
treatment, many of which require maternal engagement and participation. For example,
new research is exploring an alternative treatment approach for NAS that involves
consistent caregiver involvement. The literature addresses the influence of stigma and
importance of empathy within the context of this population. However, it is elementary in
depth and undervalued at best. The information that exists is simply not comprehensive
enough to bridge the gap between theory and action. An actual practice model that
provides evidence-based guidance on the actual delivery of services to improve outcomes
does not exist and is greatly needed. The outcome of this dissertation is the PARTNER
model, an attachment-based practice model that fills this crucial gap in the literature.

PRACTICE MODEL AND CASE STUDY RESEARCH APPROACH
This dissertation will systematically explore several aspects of perinatal opioid use
disorders to develop an evidence-informed practice model for healthcare providers
11

working with pregnant and postpartum women with opioid use disorders. This
dissertation will also explore the intersection of perinatal opioid use disorders and
attachment theory, which will serve as the framework for the PARTNER model.
The literature review is comprised of three sections that provide the foundational
context for this model. The first section of the literature review provides an examination of
the social history of opioids in the United States of America to gain a stronger, more defined
understanding of the etiology and stigma of opioid use disorders. The second section
investigates the pathophysiology of opioid use disorders, focusing in on neurobiological,
biopsychosocial, and treatment facets. This information is crucial, as it provides the
fundamental context required to truly appreciate the unique, extraordinarily arduous
facets of perinatal opioid use disorder and neonatal abstinence syndrome. The final section
of the literature review examines the pathophysiology of perinatal opioid use disorders
and neonatal abstinence syndrome and discusses how the insurmountable influence of
stigma drastically impacts this already vulnerable population.
The evidence uncovered in the literature review clearly reveals that the stigmatizing
discourse and misinformation surrounding perinatal opioid use disorders serves as a
significant barrier to early attachment development, negatively impacting one of the most
fundamentally vital aspects of life. The literature also reveals a substantial need for a
practice model that serves as guidance for providers toward fostering healthy early
attachment development rather than inhibiting it. Rooted in attachment theory, the
PARTNER model aims to foster healthy partnerships between the mother and baby, as well
as the mother and provider.

12

Composite case vignettes, informed by clinical experience and empirical literature,
are integrated throughout this dissertation. These case vignettes tell the story of Kiana, a
23-year-old black, heterosexual, cisgender woman with a perinatal opioid use disorder.
Pertinent elements of Kiana’s history are integrated throughout the literature review,
illuminating and connecting her story to the concepts that set the foundation for the
PARTNER model, and, Kiana’s story continues after the introduction of the PARTNER
model. The story of Kiana’s journey through pregnancy and the birth of her baby, William,
brings life and connection to each element of the PARTNER model.
The PARTNER model has been specifically designed with patients like Kiana and
William in mind, whose story is similar to many of the women and babies impacted by
perinatal opioid addiction. Identifying areas of antiquation and integrating strengths-based
interventions emphasizes the importance of promoting attachment between a mother and
her infant, provides a person-centered framework from which to work, and fosters insight
into and mitigation of socially-constructed barriers that deepen the divide between “us”
and “them.”

OPERATIONAL DEFINITIONS OF TERMS
The terms and concepts used throughout this dissertation are informed by and
derived from definitions from the peer-reviewed literature. Key terms and concepts
referenced in the literature review are operationally defined below for clarity and
contextual purposes. The operational definitions of new key terms and concepts utilized in
the PARTNER model will be integrated into their respective sections.
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Opioid refers to an analgesic substance intended to treat moderate to severe pain.
The term “opioid” is an umbrella term for both naturally and synthetically produced
opiates. Opioids interact with the central nervous system to create a sense of euphoria and
immense dopamine rush that the brain cannot recreate on its own, thus contributing to its
appeal and likelihood for misuse, abuse, dependency, and addiction (Centers for Disease
Control and Prevention, 2018).
There are four categories of opioids: 1) natural and semi-synthetic opioid
analgesics (including morphine, codeine, hydrocodone, and oxycodone), 2) heroin (crude
preparation of diamorphine), 3) methadone (synthetic opioid analgesic), and 4) other
synthetic opioids (including fentanyl and tramadol) (Centers for Disease Control and
Prevention, 2018).
Opioid misuse refers to the recreational and occasional, but limited, use of an opioid
or opioids with the potential for abuse or dependence (Centers for Disease Control and
Prevention, 2018).
Opioid abuse refers to recurrent, continued opioid use despite negative
consequences, including a marked decline in interpersonal relationships, physical and/or
mental health, financial stability, and/or performance at work (Centers for Disease Control
and Prevention, 2018).
Opioid dependence refers to the neurological, persistent, involuntary craving for
opioid exposure which results from neurochemical changes from consistent opioid
exposure and reward circuit activation (Galanter et al., 2015 & Wilson, 2015).
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Opioid addiction refers to behavioral, cognitive, and cyclical aspects of opioid
dependency characterized by repeated periods of preoccupation, craving, intoxication,
binging, and withdrawal. (Galanter et al., 2015 & Wilson, 2015).
Opioid withdrawal refers to the physiological symptoms that result from opioid
exposure cessation including nausea, vomiting, sweating, chills, diarrhea, and anxiety
(American Psychiatric Association, 2013).
Opioid overdose refers to a potentially fatal outcome of excessive opioid use
identified by three characteristics: decreased level of consciousness, pupil constriction, and
respiratory arrest (Centers for Disease Control and Prevention, 2018).
Opioid use disorder refers to the diagnosis of opioid dependency and addiction. The
most current edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
asserts that diagnosis involves “a problematic pattern of opioid use leading to clinically
significant impairment or distress, as manifested by at least two [criteria], occurring within
a 12-month period” (American Psychiatric Association, 2013, p. 541). Criteria for this
diagnosis include persistent desire to use, unsuccessful attempts to stop use, negative
impacts on one’s personal life, inability to fulfill obligations, tolerance development, and
withdrawal (American Psychiatric Association, 2013).
Perinatal Opioid Use Disorder refers to the diagnosis of an opioid use disorder in
the setting of the prenatal and postpartum periods of pregnancy (Galanter et al., 2015).
Neonatal Abstinence Syndrome refers to the diagnosis of observed opioid
withdrawal symptoms in infants with intrauterine opioid exposure (Gomella et al., 2013).
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Stigma refers to a socially-constructed set of negative beliefs based on assumptions,
preconceived notions, and generalizations that contribute to discrimination, exclusion,
prejudice, and rejection (Goffman, 1963).
Attachment Theory refers to the psychoanalytic approach to understanding the
influence of fundamental early relationship development on interpersonal relationships,
emotional salience, and affect regulation throughout the life cycle (Bowlby, 1969).
Attachment Pattern refers to a specific relationship development category defined
by certain behavioral characteristics (Ainsworth, Blehar, Waters, & Wall, 1978).
Attachment patterns are developed in infancy and serve as the foundation for how
relationships are structured and understood in adulthood. Secure attachment is
established from safe, nurturing, and reliable caregivers, and results in a stable, balanced
framework for relationships in adulthood. Insecure attachment is developed from
dangerous, neglectful, and unreliable caregivers, and results in a chaotic, imbalanced
framework for relationships in adulthood.
Attachment Bond refers to the actual, residual adaptive and maladaptive bonds that
result from early childhood relationship development (Bowlby, 1969); the “lasting
psychological connectedness between human beings” (Bowlby, 1969, p. 194).
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CHAPTER II: LITERATURE REVIEW
PART I: THE SOCIAL HISTORY OF OPIOIDS IN THE UNITED STATES OF AMERICA
THE ETIOLOGY OF THE OPIOID EPIDEMIC
Today, there are currently over 2.5 million people suffering from opioid dependence
in the United States with approximately 47,600 opioid overdose deaths in 2017 (Centers
for Disease Control and Prevention, 2018). The Surgeon General named this crisis as the
opioid epidemic, sweeping the nation and the world (U.S. Department of Health and Human
Services, 2016). The presence of opioids in America, though substantially increasing in
acuity over the past twenty years, is not a recently developed phenomenon. Opioids have
been used and incorporated into medical treatment for thousands of years all over the
world, but fundamentally caught the attention of Americans in the early 1900s after World
War I. Opioids, specifically morphine, were used as a method of pain relief for wounded
veterans. The popularity of opioids skyrocketed and became a common method of
treatment for just about anything, even the common cold (Heyman, 2015). It was not until
the 1920s when the government discovered the powerful addictive nature of opioids. In
response to this national problem and to mitigate this issue, Congress passed the Harrison
Narcotics Tax Act in 1914. This act strictly limited the use of opium-based substances to
licensed medical practice. Later came the Anti-Heroin Act of 1924 which prohibited the
importation and possession of opium (Courtwright, 2001 & Heyman, 2015).
Heroin regained moderate popularity in the 1950s as part of pop culture but was
generally unfamiliar to or feared by most Americans. It was not until after the Vietnam
War in the 1970s that the resurgence of heroin came back to the United States in full force
(Courtwright, 2001 & Heyman, 2015). At this point in time, the marked increase in opioid
17

overdoses led to President Richard Nixon deeming heroin the “public enemy number one”
(1971). It was at that time in July 1973 that the Drug Enforcement Agency was created
(Courtwright, 2001 & Heyman, 2015).
Attitudes toward opiates shifted significantly in the 1980s, reflected in an article
published in the New England Journal of Medicine in January 1980 by Dr. Hershel Jick and
his graduate assistant, Jane Porter. In this article, Jick and Porter attempted to refute the
risk of dependence by explicitly stating that addiction to opioids is “rare in medical patients
with no history of addiction” (Porter & Jick, 1980, p. 123). The authors’ motivation in
publishing this information remains unclear, but the subsequent sharp increase in opiate
prescriptions, dependency, and overdose over the following three decades is irrefutable
(Centers for Disease Control and Prevention, 2018 & Haney, 2017).
In the 1990s, the extensive media coverage of cocaine use became prevalent,
ostensibly overshadowing the opioid dependence problem. The Centers for Disease Control
and Prevention (2018) has identified the 1990s as the first of three overdose waves in the
United States. This wave was represented by a steep rise in prescription opioid overdose
deaths. Prescriptions for opioids were provided to patients with seemingly no limitations,
resulting in huge profits for pharmaceutical companies. When the Joint Commission on
Accreditation of Healthcare Organizations integrated pain management into vital sign
checks in the early 2000s, prescriptions and abuse increased at an astonishing rate. Based
on the prescription and healthcare management regulations in effect at that time, opioids
became more accessible than ever with little to no concern for dependency. This cause and
effect ostensibly exacerbated the addiction problem itself (U.S. Department of Health and
Human Services, 2016).
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By the end of 2010, these remarkable changes in opioid access and abuse came to
the forefront of the medical community. The Centers for Disease Control and Prevention
(2018) marked 2010 and 2013 as the second and third overdose waves, signified by a
marked rise in heroin overdose deaths and synthetic opioid overdose deaths, respectively.
Since this time, the federal government has implemented prescription drug monitoring
programs, as well as stricter guidelines and legal consequences for inappropriate and/or
excessive prescribing. Training and education on naloxone, an emergency treatment that
counteracts opioid overdose more commonly known by the brand name NARCAN, has been
widely expanded as well. Efforts to reduce access and treat dependency have vastly
increased, but statistical evidence strongly indicates that something is not working
(Centers for Disease Control and Prevention, 2018).
It was not until June 2017 that the New England Journal of Medicine publicly
addressed the illegitimacy and irresponsibility of that 1980 article, now commonly referred
to simply as “Porter and Jick.” In its response, committee members of the Journal explicitly
recognized the original content as empirically unsupported and a contributor to the
current opioid epidemic, as it minimized the risk and severity of addiction related to
opiates. In addition, the Journal cited lawsuits against pharmaceutical companies that also
misrepresented the risk of dependence to doctors and patients (Leung, Macdonald,
Stanbrook, Dhalla, & Juurlink, 2017). Shortly after the publication of this 2017 letter, Dr.
Jick was quoted in an interview saying the New England Journal of Medicine has “published
nearly 400 papers on drug safety, but never before have we had one that got into such a
bizarre and unhealthy situation” (Haney, 2017, p. 1). Jick admitted “if I knew then what I
know now, I would have never published it” (Haney, 2017, p. 1).
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In 2016, a year prior to this response, the first U.S. Surgeon General report on
addiction was published. In the preface, Dr. Vivek Murthy, the U.S. Surgeon General at the
time, acknowledged the need for not only addiction treatment reform, but a reform of the
discourse surrounding addiction as well. Dr. Murthy stipulates that the way in which
society approaches addiction conveys a false, stigmatizing message that addiction is a
moral failing rather than a chronic illness. In this report, Dr. Murthy stated:
We also need a cultural shift in how we think about addiction. For far too long, too
many in our country have viewed addiction as a moral failing. This unfortunate
stigma has created an added burden of shame that has made people with substance
use disorders less likely to come forward and seek help. It has also made it more
challenging to marshal the necessary investments in prevention and treatment. We
must help everyone see that addiction is not a character flaw – it is a chronic illness
that we must approach with the same skill and compassion with which we approach
heart disease, diabetes, and cancer. (p. v)
This stigma imposes shame and creates barriers to treatment, which only works toward
perpetuating the opioid epidemic rather than ending it (U.S. Department of Health and
Human Services, 2016).
CASE STUDY VIGNETTE
At age 20, Kiana was involved in a motor vehicle accident. She was seen and
evaluated in the emergency department of a local hospital, presenting with complaints
of neck pain and a headache. Kiana was given a 30-day prescription for Percocet
without any education on risk of dependency. Kiana did not know how to evaluate and
treat her own pain appropriately at home (i.e. take an over-the-counter analgesic for
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lower/moderate pain relief), and Kiana assumed that because she was given this
prescription by a physician, it was safe to finish the prescription to the end and take
them every day. She thought she was doing what she was supposed to do.

THE STIGMA OF OPIOID DEPENDENCY AND ADDICTION
Despite historical implications, scientific evidence that distinguishes an opioid use
disorder as a pathology-driven disease, and empirically identified risk factors associated
with opioid use disorders, the stigma surrounding opioid dependency and addiction is
palpable.
The concept of social stigma was first explored and defined by sociologist, Erving
Goffman. Goffman identified stigma as a phenomenon involving perceptual classification of
people as either normal or undesirable based on societally-constructed beliefs. Goffman
also identified three groups of people related to a stigma:
1) the stigmatized, characterized by individuals or groups who are associated with and
impacted by the stigma,
2) the normals, characterized by individuals or groups who are not associated with nor
impacted by the stigma, and
3) the wise, characterized by individuals or groups who are not associated with nor
impacted by the stigma, but are fundamentally aware of the stigma and the way in
which it impacts the stigmatized (Goffman, 1963).
Empirical research has supported Goffman’s theory, with the identification of two
subgroups that exist within the wise:
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1) the active wise, characterized by individuals or groups who work toward and
advocate for the deconstruction of a stigma, and
2) the passive wise, characterized by individuals or groups who take a more
submissive, indifferent stance (Smith, 2012).
Stigma has several detrimental consequences on the stigmatized individuals and
groups themselves, including direct effects on self-esteem and mental health and
willingness to seek out healthcare and treatment, as well as other harm reduction
modalities. The false, unsubstantiated attributes of the stigma are often internalized as
reality for the stigmatized, resulting in a decreased sense of self-worth. Stigma generates a
destructive sense of external condemnation and fear of poor quality of care, legal
ramifications, and judgment from healthcare providers.
This is a significant issue within the societal context of addiction, as these associated
schemas and rhetoric further marginalize and shame an already at-risk population. Opioid
dependency and addiction is often considered a moral failing with full responsibility placed
upon the person suffering. This stigma is particularly damaging, as it directly attacks the
integrity, dignity, and value of the person as a human being (Ahern et al., 2007; Earnshaw,
Smith, & Copenhaver, 2013; Lloyd, 2013; Racine et al., 2017). Stigma can serve as a
profound, biopolitical, institutionally-created barrier and deterrent to healthcare and
treatment (Ahern, 2006; Corrigan, 2004; Fraser et al., 2017; Goffman, 1963; Kelly et al.,
2016; Lloyd, 2013; Major & O’Brien, 2005; Racine et al., 2017; Woo et al., 2017).
CASE STUDY VIGNETTE
Kiana continued to take the Percocet prescription every day and, as she got
closer to the 30-day mark, she noticed the bottle would be finished within a just few
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days. Kiana went to her pharmacy to request a refill but was told there were no refills
available and that she needed another prescription. Kiana returned to the same
emergency department to ask for another prescription, as instructed. Shortly after
being evaluated, she overheard some staff members talking about “the drug seeker in
bed 10.” She looked at her wristband and noticed that she was in bed 10. They were
talking about her.
Rather than assessing for opioid dependency or offering psychoeducation, a
physician provided her with another prescription and told her “this is the last one.”
Kiana took the prescription, feeling confused, embarrassed, and ashamed. She said to
herself “well, I’m not going back there.”
A few days later, Kiana told her best friend, Ann Marie, about what happened.
Ann Marie responded in disbelief. “What? That’s crazy! A drug seeker? They’re the ones
that gave it to you in the first place! You’re no dope fiend. Have you seen those
people?” Kiana thought to herself, “Ann Marie is right, it’s not like I’m one of them.”
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PART II: THE PATHOPHYSIOLOGY OF OPIOID DEPENDENCY AND ADDICTION
NEUROBIOLOGICAL INTERACTIONS OF OPIOIDS AND THE BRAIN
The perception of addiction as a moral failing often overshadows the
pathophysiology of addiction. To understand the dangerous allure of opioids, the first place
to investigate is the brain. The brain is run by neurotransmitters, chemical molecules that
send messages all throughout the body. Dopamine, a neurotransmitter naturally produced
within the brain, instinctively regulates the brain’s reward-motivation system and guides
motivational salience. Motivational salience is a cognitive process that influences the way
in which potential actions are evaluated, and, therefore, how the individual behaves in
response to these evaluations. Cortisol, another naturally-produced neurotransmitter, is
responsible for regulating stress. No two brains are exactly alike; there are several genetic
and learned factors that contribute to the amount of dopamine and cortisol receptors exist
in the brain (Applegate & Shapiro, 2005; Evans & Cahill, 2016; Maguire, 2013; Walter et al.,
2015; Wilson, 2015).
Dopamine and cortisol levels are significantly impacted by exposure to opioids.
Almost immediately after being consumed, opioids are absorbed in the bloodstream,
making their way to the brain and attach themselves to receptors. They flood the limbic
system value circuit with dopamine, and cortisol production is reduced. This rush of
increased dopamine and decreased cortisol produces a sensation of physical and mental
euphoria (Bisaga, Chernyaev, & McLellan, 2018; Evans & Cahill, 2016; Walter et al., 2015;
Wilson, 2015).
When exposed to sharp increases in dopamine generated by opioids, the brain
identifies, classifies, and retains these preceding actions and behaviors as high reward-
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value and, ultimately, high incentive-value. The baseline dopamine that exists in the brain
increases. Because the enormous amount of dopamine generated by opioids cannot be
duplicated by the brain on its own, the brain essentially becomes trained to crave the
dopamine-manufacturing substance. The brain becomes dependent on opioid exposure to
function at baseline (Applegate & Shapiro, 2005; Evans & Cahill, 2016; Wilson, 2015).
When these dopamine levels drop below the new, increased baseline threshold, the
brain excretes increased cortisol. This action contributes to opioid withdrawal,
characterized by symptoms opposite of euphoria. When this occurs, the brain remembers
that those actions and behaviors that preceded the opioid ingestion will result in the craved
dopamine increase and cortisol decrease. In essence, the brain has been chemically trained
to subconsciously associate opioid use with positive neural rewards (Applegate & Shapiro,
2005; Evans & Cahill, 2016; Wilson, 2015).
From the neurobiological perspective, dependency and addiction can be
conceptualized as a reward deficit disorder with changes in impulse control and executive
functioning (Herron & Brennan, 2015). Opioid dependency can be characterized by the
brain’s physiological need for opioid exposure to maintain its baseline functioning. Opioid
addiction can be characterized by the actions and behaviors that precede the opioid
exposure. These actions and behaviors are generally characterized by people, places, and
objects and serve as triggers for continued use, cravings, and relapse. Once a dependency
and addiction is developed, recovery can be extremely challenging, but it is not impossible.
The neuroplasticity of the brain allows for these neural pathways and learned rewards are
adaptable and reversible (Evans & Cahill, 2016; Wilson, 2015).
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CASE STUDY VIGNETTE
It was two months and two prescriptions since the car accident. Kiana was
again almost out of Percocet and was trying to ration what she had left. However, she
started noticing that when she stopped taking the Percocet for a couple of days, she
felt terrible. She felt like she had the flu with symptoms of nausea, vomiting, insomnia,
and night sweats. She thought to herself, “Wow. I must be really messed up from that
car accident. I need this stuff.” What Kiana didn’t realize is that these were not
symptoms from the car accident. She was experiencing opioid withdrawal.
Kiana began to wonder how she could get another prescription for Percocet
before running out of what she had left. She did not want to feel like this anymore. She
considered going to the emergency department, but immediately thought back to the
terrible way staff made her feel. Kiana started to subtly ask around to see if anyone she
knew had Percocet she could buy. Shortly after her search began, she discovered that a
friend of a friend, Walter, was selling Percocet. However, the pills came with a steep
price tag.
Walter told Kiana that he could offer her heroin instead, explaining that heroin
was “way cheaper” and “way stronger.” Kiana took a moment to think it over, but the
decision was made before he could even finish his sentence. She bought the heroin and
left. She told herself, “It’s not like I’m doing it all day, every day. And, I’m working two
jobs! This is just temporary until I can get this under control. I’m not one of those
people.”
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BIOPSYCHOSOCIAL RISK FACTORS
In addition to neurobiological implications, there are other biopsychosocial factors
and impacts on the learning brain that impact the risk of opioid misuse, abuse, dependency,
and addiction. Three of the most empirically significant components include biological
factors, adverse childhood experiences, and psychosocial/environmental factors (AitDaoud et al., 2017; Applegate & Shapiro, 2005; Berlin, Shanahan, & Appleyard Carmody,
2014; Centers for Disease Control and Prevention, 2018; Covington, 2008; Galanter et al.,
2015; Goodman, Milliken, Theiler, Nordstrom, & Akerman, 2015; Herron & Brennan, 2015;
Khoury et al., 2010; Maguire, 2013; Torchalla et al., 2014; Wilson, 2015).
BIOLOGICAL FACTORS
Biological influences on risk for addiction include genetics, gender, and neurologic
and biochemical factors (Herron & Brennan, 2015; Maguire, 2013). As a demographic
characteristic, women are experiencing increases in opioid use disorders at alarmingly
higher rates than men, and women are more likely to develop and suffer longer from opioid
use disorders. Since 1999, the number of opiate overdose deaths among women has
increased by 400%, compared to 265% among men. Statistical evidence also indicates that
women progress from initial use to opioid use disorders much more rapidly than men
(Centers for Disease Control and Prevention, 2018).
Studies aimed to examine the relationship between women and opioid use disorders
is still an underdeveloped area of research. However, the existing research does identify
biological and social factors that contribute to the higher occurrence of opioid use
disorders in women. Researchers have identified some potential factors that play a role in
this dynamic, including hormones and predisposition to some chronic medical conditions.
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Lab research has identified some connections between sex hormones and likelihood of
opioid dependency. Further research shows women experience higher rates of chronic pain
illnesses for which opiate pain medication is prescribed (Ait-Daoud et al., 2017 & Maguire,
2013). From a social standpoint, women are at higher risk than men for experiencing
shame and stigma and barriers to financial, medical, and housing resources (Ait-Daoud et
al., 2017 & Covington, 2008). Women also experience substantially higher rates of
experiencing mental health challenges, internalized and externalized family role identity
complexities, and physical and sexual abuse (Covington, 2008).
According to the National Institute on Drug Abuse (2010), there is an extremely high
prevalence of comorbid substance use disorders and another mental health diagnosis.
More specifically, research reveals that those diagnosed with a mood, anxiety, traumarelated, or stressor-related disorder are at the highest risk of developing a substance use
disorder (National Institute on Drug Abuse, 2010). Furthermore, women who experience
postpartum depression are at added risk for developing substance use and potential
dependency (Ait-Daoud et al., 2017).
There are several challenges that exist within the examination of substance use
disorders and mental illness. While research does indicate a significant relationship
between mental health and substance use disorders, it is sometimes impossible to
determine which problem precedes the other. In some cases, drug use increases symptoms
of preexisting mental illnesses that may or may not have already been identified. The fact
that substance use can alter brain chemistry makes this distinction even harder to identify.
In other cases, drug use occurs after the mental health symptoms manifest. It is also
difficult to generalize the extent to which one impacts the other, as the level and intensity
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of addiction and mental illness varies so greatly (National Institute on Drug Abuse, 2010).
Regardless of epidemiology, risk for both substance use disorders and mental health issues
is increased by overlapping external determinants, including psychosocial and
environmental factors (Galanter et al., 2015; Herron & Brennan, 2015; Khoury et al., 2010;
Torchalla et al., 2014; Wilson, 2015).
CASE STUDY VIGNETTE
Kiana grew up in Philadelphia, Pennsylvania in a modest home with her
mother, father, and two younger sisters. Her father worked as a chef in a restaurant
and her mother stayed at home. Every so often, her parents struggled to make ends
meet, but they were generally able to get by. Kiana’s family lived in one of the lowerincome neighborhoods in the city, but she often thought to herself that it could “always
be worse.” Kiana viewed her household with the same mentality, and from the outside
looking in, things seemed okay. However, Kiana’s home life was chaotic.
Kiana’s father struggled with alcohol abuse and bipolar disorder. He viewed
asking for help as a sign of weakness, so he never received any kind of counseling or
medication management. He often came home from work late at night with the smell
of liquor on his breath. Her parents fought frequently, especially when alcohol was
involved. Her father was verbally, and sometimes physically abusive toward her, her
mother, and her younger sisters. Her parents divorced when she was 15 and she has
only seen her father a handful of times since then, but she lived in fear of him for as
long as she could remember.

29

ADVERSE CHILDHOOD EXPERIENCES
Adverse childhood experiences, also referred to as ACEs, are stressful, traumatic
events that occur specifically in childhood and have been empirically linked to negative
health outcomes, including addiction. The concept of ACEs originates from a longitudinal
study conducted by Kaiser Permanente and the Centers for Disease Control, that examined
the relationship between traumatic, stressful childhood experiences and health outcomes
in adulthood. The ACEs study included a wide variety of stressful and/or traumatic
experiences such as witnessing and/or experiencing verbal and/or physical abuse, low selfesteem and self-worth, disruptions within the function of the family system, family history
of addiction and/or mental illness, and lack of access to basic needs including food, shelter,
and safety (Felitti et al., 1998).
The strong correlation discovered between ACEs and health outcomes was
extraordinary, revealing a significant relationship between one’s ACE score and negative
health outcomes. As an ACE score increases, so does one’s risk for physical illness and
social and emotional problems. With an ACE score of just 4, individuals begin to face
significant challenges, including increased risk for and occurrence of physical illness (i.e.
heart disease, obesity, cancer, liver disease), mental illness (depression, anxiety, suicidal
ideation, alcohol and substance use disorders), and interpersonal issues (interpersonal
violence, intimate partner violence, homelessness, unemployment). The occurrence of
multiple ACEs is synergistic, meaning the interaction between each ACE produces a greater
combined effect than the sum of each individual ACE effects. This study also revealed that
adverse childhood experiences are incredibly common. Approximately 64% of the 17,000
surveyed adults reported at least one ACE occurrence (Felitti et al., 1998). Since that time,
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numerous other studies have been conducted amongst a variety of populations with
consistent, significant results (Centers for Disease Control and Prevention, 2016).
CASE STUDY VIGNETTE
In high school, Kiana was referred to the school psychologist due to truancy
issues. Kiana’s evaluation involved an extensive assessment, including the Adverse
Childhood Experience (ACE) Questionnaire, which resulted in an astonishing score of
8/10. Kiana was diagnosed with depression and posttraumatic stress disorder and was
referred to a psychiatrist and therapist. Kiana was reluctant to follow through with
this recommendation but did so anyway to appease her mother.
Kiana saw a counselor for a few months but stopped when she graduated from
high school and got a full-time job at a local restaurant. She actually had started to
like counseling, but, when left with the decision to prioritize herself or work double
shifts to help support her mother and two younger sisters, she chose the latter.

PSYCHOSOCIAL/ENVIRONMENTAL FACTORS
There are empirically significant connections between addiction and trauma
experienced in adulthood as well. Psychosocial factors, including interpersonal and
environmental influences, have a strong impact on risk for addiction. One of the most
impactful influences on risk for addiction is psychological trauma, referring to trauma that
meets criteria for acute stress disorders (i.e. posttraumatic stress disorder) and complex
trauma (Berlin et al., 2014; Goodman et al., 2015; Herron & Brennan, 2015; Khoury et al.,
2010; Maguire, 2013). Trauma is vast and all-encompassing; it refers to the single- or
multi-occurrence of a psychologically distressing experience, the way in which that
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experience is uniquely and collectively processed, and the short- and long-term impact of
the experience. These traumas can include, but are not limited to, physical, sexual, and
emotional abuse and/or neglect. (Khoury et al., 2010). Over half of women with addiction,
who are already predisposed to risk for addiction based on their gender alone, meet
criteria for posttraumatic stress disorder (Goodman et al., 2015). When exposed to trauma,
the developing brain produces less dopamine, leaving the brain to seek out external
sources of dopamine production (Applegate & Shapiro, 2005).
Environmental influences on risk for addiction include internal and external factors
that contribute to stress, alienation, and/or isolation. Examples of external factors include
socioeconomic status, minority status, neighborhood/community violence, household
dysfunction, and lack of access to resources. Communities with higher rates of crime,
violence, and poverty are linked to increased risk for substance experimentation and
substance use disorders (Galanter et al., 2015; Herron & Brennan, 2015; Maguire, 2013).
However, these statistics are not always the rule. There are many members of
impoverished, disenfranchised communities who never experiment with substances or
develop an addiction. Internal factors, such as resiliency and individual response to
external environmental stressors, also influence risk for addiction (Maguire, 2013).
CASE STUDY VIGNETTE
Shortly after Kiana graduated from high school, she started her new job at a
restaurant in the nearby neighborhood. One night, while walking home from a latenight work shift, Kiana was raped at gunpoint. Kiana never talked to anyone about
what had happened to her that night. She didn’t even want to think about it. She just
wanted to pretend it never happened.
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A few weeks later, Kiana discovered that she was pregnant. She hadn’t been
sexually active with any other partners, so she knew the pregnancy resulted from the
rape. Kiana only ever disclosed the rape and pregnancy to her best friend, Ann Marie.
“I don’t want to talk about it, I’m fine” Kiana said. “Just please take me to the nearest
abortion clinic and don’t mention this to anyone.” Over the next few months, Ann Marie
made several offers to help Kiana file a police report or find a counselor. Kiana always
declined and said she was “completely fine.”

OPIOID USE DISORDER TREATMENT APPROACHES
There are many models of and approaches to substance use disorder treatment.
This section will review the four umbrella modes of treatment that are specifically geared
toward opiate addiction. These methods include detoxification, twelve-step recovery,
behavioral treatment, and medication-assisted treatment. These treatment modalities can
be used independently of or in conjunction with one another.
DETOXIFICATION
The most common method of treatment for opioid use disorders is detoxification,
which involves rapid cessation of use while being monitored in a controlled medical
setting, such as a hospital. Despite its widespread utilization, detoxification has been shown
to be exceptionally ineffective and has little to no short- or long-term benefits. This is
especially evident when detoxification is not immediately followed by another form of
treatment. Most of those who complete the detoxification process relapse shortly afterward
(Herron & Brennan, 2015 & Galanter et al., 2015).
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TWELVE-STEP RECOVERY
Twelve-step recovery, founded in 1935, involves structured, community-based
support groups for people with substance use disorders. They are intended to be safe,
judgment-free, and facilitated by group members themselves. There are several groupings
of twelve-steps that address specific substances, like Narcotics Anonymous. They are
generally free of charge, aside from optional donations, and are held in various types of
community centers. Group members are entitled to a sponsor, who is typically a member of
the group who has maintained sobriety and able to serve as a mentor to newer group
members. The twelve-step model functions as a set of principles for leading a moral life,
while simultaneously guides participants through the journey of achieving and maintaining
sobriety (Herron & Brennan, 2015 & Galanter et al., 2015). Though twelve-step groups are
not considered to be treatment and are not recommended to be utilized as the sole source
of recovery, they have been shown to be successful in aiding recovery (Fiorentine &
Hillhouse, 2000).
BEHAVIORAL TREATMENT
Behavioral treatment for substance use disorders involves theoretically-rooted,
evidence-based psychotherapy and are delivered in a combination of inpatient, outpatient,
group and individual settings. Most behavioral treatment approaches utilize Prochaska and
diClemente’s model of change as its foundation, which identifies five stages of addiction
recovery. These five stages include:
1) Precontemplation, which involves no concrete intention to take action within the
foreseeable future;
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2) Contemplation, which involves intention to take action within the foreseeable
future (approximately six months or less);
3) Preparation, which involves intention to take action in the immediate future
(approximately one month);
4) Action, which involves making specific, measurable, observable changes in
behavior; and
5) Maintenance, which involves actively working to prevent relapse (Herron &
Brennan, 2015).
The theoretical approaches with the strongest evidentiary support include
motivational interviewing, cognitive behavioral therapy, relapse prevention, and solutionfocused therapy. Group and family treatment approaches are also very well-supported.
Behavioral treatment programs can be especially beneficial for those who have a comorbid
mental illness that contributes to challenges in maintaining sobriety (Herron & Brennan,
2015 & Lewis, 2014).
MEDICATION-ASSISTED TREATMENT
The DSM-5 identifies maintenance therapy, also referred to as medication-assisted
treatment, as one specifier of the opioid use disorder diagnosis. This additional specifier is
used “if the individual taking a prescribed agonist medication such as methadone or
buprenorphine and none of the criteria for opioid use disorder have been met for that class
of medication (except tolerance to, or withdraw from, the agonist)” (American Psychiatric
Association, 2013, p. 541).
Medication-assisted treatment programs are evidence-based and involve a
combination of medication and, in some cases, behavioral treatment intervention.
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Medications used for medication-assisted treatment are either full agonists or partial
agonists. Full agonists attach to receptors in the brain to the fullest extent without a ceiling
effect. The presence of full agonist molecules correlates directly to the neurological effects.
Partial agonists attach to receptors in the brain as well, but at only about 50 percent. Partial
agonists have a ceiling effect, meaning that once the drug attaches to the receptor to its
fullest extent, the addition of more agonist molecules has no effect (Bisaga et al., 2018;
Herron & Brennan, 2015).
The three medications used in medication-assisted treatment programs for opioid
use disorder management include:
1) methadone, a full agonist
2) buprenorphine, a partial agonist
3) naltrexone, an antagonist.
These three medications were not developed or introduced as treatment options
until the mid-1960s. Though they are different prescriptions, they behave similarly to one
another in the opioid use disorder treatment process. Methadone, buprenorphine, and
naltrexone interact with the nervous system and can reduce pain but lack the chemical
compound that contributes to euphoria. Methadone and buprenorphine are most often
dispensed at clinics, where the patient may also receive group and/or individual counseling
to help treat the behavioral aspect of the addiction while their physical dependency is
addressed with the medication (Bart, 2012). Naloxone (also known as NARCAN) is a shortterm antagonist that is primarily used in the acute setting of an overdose to reverse the
effect of the opioid, rather than as an ongoing, maintenance medication (Herron & Brennan,
2015).

36

CASE STUDY VIGNETTE
Kiana was able to keep her heroin use a secret until she had her first overdose
shortly after she turned 23 years old. Kiana had tried to stop using heroin cold turkey
the week before, managing to go four days without using until the cravings and
withdrawal symptoms felt out of control. On the verge of relapse, she called Walter
and bought double the amount of heroin she was used to taking in hopes of
immediately reversing the gut-wrenching withdrawal.
Kiana had seen the horror of several friends’ overdoses, but in this moment, the
urge to use seemingly drowned out this entire thought process as she injected the
heroin into her arm. The cravings and withdrawal were overwhelming and ostensibly
took over her body. And then, everything went dark.
When Kiana woke up, she was laying in the ground surrounded by paramedics.
Kiana felt disoriented and everything was blurry, but she immediately knew what
happened. She realized she had just overdosed. When the paramedic told her he just
gave her NARCAN, Kiana started sobbing and apologizing. The paramedic could tell
this was her first overdose and he assured her that she’d be able to get help when they
got her to the hospital. But, the Kiana heard nothing he said. The sound of the
paramedic’s voice was muffled by her deafening thoughts. “I’m one of them, I’m one of
them.”
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PART III: THE PATHOPHYSIOLOGY OF PERINATAL OPIOID USE DISORDERS
PERINATAL OPIOID USE DISORDERS
Paralleling the general population, there has been a marked increase in incidence of
perinatal opioid use disorders. Although there are no statistics available that directly
measure incidence of perinatal opioid use disorders directly, hospitals saw an increase in
opioid-exposed infants from 1.5 cases per 1,000 births in 1999 to 6 cases per 1,000 births
in 2013 (American College of Obstetrics and Gynecology, 2017). Opioid use disorders
become significantly more complicated during pregnancy due to several factors including
differences in treatment options and barriers to care, both concrete and sociallyconstructed in nature. Perinatal opioid use disorders have unique challenges and
considerations in terms of the prenatal and postpartum periods, as well as differential
experiences and needs for the mother and the baby (American College of Obstetrics and
Gynecology, 2017; Tauger, 2017; Wendell, 2013).
Intrauterine substance exposure occurs when a pregnant woman has consumed a
substance that passes the placental wall and blood-brain barrier of the fetus. The amount of
fetal exposure and incidence of withdrawal is dependent on the amount and frequency of
substance use, as well as the physiological makeup of the placenta and fetus itself (Galanter
et al., 2015; Gomella et al., 2013; Hudak & Tan, 2012). As previously mentioned, evidencebased research indicates that opioid dependence can be successfully treated with
abstinence-oriented treatment and medication-assisted treatment programs. For pregnant
women, however, abstinence-oriented treatment programs are not medically
recommended due to risk of relapse and mortality. Though acute opioid withdrawal is
uncomfortable for adults, there are no risks of fatality. The risk of fatality to the fetus,
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however, is extremely high (American College of Obstetricians and Gynecologists, 2017).
These treatment limitations are also accompanied by barriers. Access to medicationassisted treatment can be challenging depending on geographical location, insurance
coverage, and willingness and capacity for providers to treat addiction during pregnancy.
This is especially challenging for women who seek out initiation of treatment during
pregnancy (American College of Obstetricians and Gynecologists, 2017).
Infants exposed to methadone or buprenorphine are at risk for the same symptoms,
but at a decreased level (Behnke, M. & Smith, V., 2013; Shaefer, Peters, & Miller, 2015).
Research has consistently shown lower severity of symptoms and length of treatment for
NAS among babies with intrauterine buprenorphine exposure in comparison to babies with
intrauterine methadone exposure (Jones et al., 2005 & Jones et al., 2008). Naloxone, though
safe to prescribe in general, is not prescribed to pregnant women due to lack of evidence
that supports safety to the fetus (Jones et al., 2008).
CASE STUDY VIGNETTE
After arriving at the emergency department, the medical team told Kianna they
needed to complete a full workup and run some routine labs, including a urine drug
screen, complete blood count (CBC), and, because Kiana is a female, a pregnancy test.
Kiana laid on the stretcher in the room by herself for a few hours, reflecting back on
the time she was given that very first Percocet prescription in this exact same
emergency room three years ago. She told herself that this is her rock bottom; this was
her wake-up call. She decided she was going to muster up the courage to ask the
doctor for help when she came back with the test results.
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However, the conversation about getting treatment that she had played out in
her head came to an abrupt halt when she was told her pregnancy test is positive.
Countless thoughts and questions started speeding through her mind. Within an
instant, Kiana froze on one question – what’s going to happen to the baby?

NEONATAL ABSTINENCE SYNDROME (NAS)
Neonatal abstinence syndrome occurs when an infant with intrauterine substance
exposure is born dependent on the substance exposed and starts to show symptoms of
withdrawal after birth. NAS can be caused by many licit and illicit substances aside from
opioids and their agonists, including alcohol, caffeine, and SSRIs. Approximately 60-90% of
infants exposed to opioids in utero are diagnosed with and treated for NAS (Galanter et al.,
2015 & Gomella et al., 2013). The American Academy of Pediatrics recommends that babies
with exposure to opioids or opioid-like substances remain in the hospital for at least five
postpartum days to monitor for NAS (Hudak & Tan, 2012).
The onset of withdrawal symptoms can range from immediately after birth to
several days after birth, hence the American Academy of Pediatrics’ recommendation for
extended admission for monitoring. Infants with suspected NAS are typically evaluated
using the Modified Finnegan’s Scoring System for Neonatal Withdrawal, a scoring system
comprised of subjective and objective withdrawal observations (Finnegan, Connaughton,
Kron, & Emich, 1975). The occurrence of three consecutive scores of seven or greater is
indication for treatment (Gomella et al., 2013; Hudak & Tan, 2012; Schaefer et al., 2015).
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PHARMACOLOGICAL TREATMENT
Pharmacological treatment for NAS involves administration of a like drug, one that
interacts with the same receptors as the drug of exposure. For instance, infants with
intrauterine exposure to opiates are often treated with morphine, an opiate that acts on the
same receptors. In some cases, other drugs like phenobarbital or clonidine are used in
conjunction with the like drug to manage exacerbated withdrawal symptoms. Medication is
administered and titrated based on withdrawal symptoms as indicated by the Modified
Finnegan’s Scoring System for Neonatal Withdrawal, which involves both subjective and
objective observations (Gomella et al., 2013 & Kraft, Stover, & Davis, 2016).
Infants treated for NAS have an average hospital length of stay of 21 days, whereas
the average length of stay for an otherwise healthy newborn is up to three days. This
extended length of stay in the neonatal critical care setting is incredibly expensive and a
drain on medical resources. National hospital expenses for NAS treatment (adjusted to
reflect inflation) increased from $190 million in 2000 to $720 million in 2009 (Patrick et
al., 2012). As an effort to mitigate these rising healthcare costs, new empirical research is
being generated to measure the efficacy of non-pharmacological treatment approaches in
addition to the preexisting pharmacological approaches.
NONPHARMACOLOGICAL TREATMENT
Although analgesics are the current standard of care for NAS treatment, there are
also nonpharmacological methods that can be implemented as well. The most thoroughly
researched approaches include breastfeeding, bonding, swaddling, and cuddling, lowstimulus environments, and increased family involvement, primarily the parent(s) of the
baby. Several empirical research studies suggest that incorporating these
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nonpharmacological factors into treatment planning leads to a remarkable decrease in
withdrawal symptoms, length of hospital stay, and hospital costs (Boucher, 2017; Gomella
et al., 2013; Grossman, Lipshaw, Osborn, & Berkwitt, 2018; Holmes et al., 2016; Howard et
al., 2017; MacMullen, Dulski, & Blobaum, 2014; Maguire, 2014; Newman et al. 2015; Patrick
et al., 2016; Pritham, 2013; Short, Gannon, & Abatemarco, 2016; Velez & Jansson, 2008).
Despite the benefits of breastfeeding on neonatal abstinence treatment outcomes,
breastfeeding and co-occurring opioid use, both prescribed or illicit, is contraindicated.
However, there are no known contraindications of breastfeeding and co-occurring
methadone and/or buprenorphine use (American College of Obstetricians and
Gynecologists, 2017).
OUTCOMES FOR INTRAUTERINE OPIOID EXPOSURE
Infants with opioid exposure in pregnancy, including methadone and
buprenorphine, have an overall strong prognosis in terms of physical and behavioral
outcomes in the infancy period. Intrauterine opioid exposure has minimal, if any, influence
on fetal growth, congenital anomalies, or neurological outcomes (Behnke et al., 2013).
Aside from withdrawal, the two short-term risks identified by the literature included an
increased risk for sudden infant death syndrome and strabismus, a treatable misalignment
of the eyes. In terms of neurodevelopment, infants with intrauterine opioid exposure
generally catch up to their non-exposed peers by one to two years of age, with the vast
majority functioning within the normal range of mental and motor development by five to
six years of age (Gomella et al., 2013; Logan, Brown, & Hayes, 2013; Maguire et al., 2016).
Infants with intrauterine opioid exposure, including methadone and
buprenorphine, also have an overall strong prognosis in terms of physical and behavioral
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outcomes across childhood, adolescence, and adulthood. Intrauterine opioid exposure has
minimal, if any, influence on long-term physical development, behavior, cognitive and
executive functioning, speech and language development, academic achievement, or
predisposition to opioid dependency and/or addiction later in life (Behkne et al., 2013).
Current research suggests that the environment in which the child grows up has a more
significant impact on outcomes. Infants who are raised in nurturing, supportive, stable
homes with access to resources are more likely to reach the positive neurodevelopmental
outcomes than their counterparts who are raised in neglectful, inconsistent, and unstable
home environments. Early infancy and childhood attachment development between infants
and their caregivers decreases this risk. These social and family protective factors also
decrease risk for opioid use, dependency, and addiction later in life as well (Herranz, 2014;
Logan et al., 2013).
CASE STUDY VIGNETTE
Kiana has wanted to be a mother for as long as she could remember. Her first
sister was born when she was seven, and the second was born when she was nine. Her
earliest memories include being her mother’s “big sister helper,” handing her mother
diapers and choosing which of her favorite books she’d read to “her” baby before
bedtime. She spent every summer taking her sisters to the park and the community
pool, always taking on the role of “the mommy” when they’d play make-believe.
The idea of being “mommy” came to light again about a year ago when Kiana
met her boyfriend, Matthew. They talked about getting married and starting a family
one day. They even talked about their favorite baby names – William, meaning
“protector,” for a boy or Briana, meaning “strong,” for a girl. They both knew, however,
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that these dreams would have to remain dreams until Kiana addressed her addiction.
Kiana knew what it was like to grow up in a house filled with addiction and chaos. She
always dreamed of giving her children a better life than the one she lived herself.

THE STIGMA OF PERINATAL OPIOID USE DISORDERS
The stigma that exists toward opioid dependency and addiction is monumentally
amplified in the setting of perinatal opioid use disorders. Empirical research consistently
identifies stigma, guilt, and shame as the biggest challenge for mothers with prenatal
substance use disorders. Unfortunately, there is very limited research on stigma and
pregnancy in terms of substance use disorders. The standing research does indicate that
stigma exists amongst mothers who give birth to an infant with NAS due to opioid,
methadone, and buprenorphine exposure, but it is very preliminary in nature and provides
little direction for change.
Across the literature, these women have reported feeling ostracized and
misunderstood, consistently being met with misconceptions and prejudicial mindsets. This
research consistently reveals that pregnant and postpartum women with opioid use
disorders experience judgment, indifference, stigmatization, embarrassment, and anxiety
when interacting with healthcare providers. They experience shaming verbal and
nonverbal language of healthcare staff, subjective NAS scoring, and the exclusion of the
mother from participating in the treatment plan for both herself and for her baby. They
also describe fears surrounding child protective service involvement, particularly
surrounding the secretive nature of mandated reporting procedures, the sharing of medical
information, and lack of transparency in the discharge planning process. The power and
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influence of language choice, perception, and social stigma becomes the focus forefront,
rather than attachment and bonding between the mother and the infant (Cleveland, 2013;
Cleveland & Bonugli, 2014; Cleveland et al., 2016; Dimirci et al., 2015; Goodyear-Smith &
Buetow, 2001; Holbrook, 2015; Holbrook & Nguyen, 2015; Howard, 2015; Howard, 2016;
Jones et al., 2008; Mattocks et al., 2017; Stengel, 2014; Stone, 2015; Suchman & Luthar,
2000).
The existing research, in fact, corroborates these experiences. The literature reveals
that health care providers acknowledge having negative, judgmental thoughts and feelings
toward pregnant and postpartum women with opioid use disorders. They also report
experiencing heightened stress when working with this population due to maternal
defensiveness, difficulty with engagement, and concern for the baby’s wellbeing (Fraser et
al., 2007; Maguire, Webb, Passmore, & Cline, 2012; Murphy-Oikonen, Brownlee,
Montelpare, & Gerlach, 2010).
It has become clear that there is a cyclical relationship between the perceptions of
both the mothers and the providers. It is emotionally grueling for a mother to watch her
infant experience withdrawal. Many women in this position feel tremendous guilt and
blame themselves for being the cause of their baby’s distress. Unfortunately, many of these
women are further hindered by limited coping skills to help them process the situation. At
this point, maladaptive coping mechanisms come into play, including defensiveness,
disengagement, and decreased or lack of visitation. In turn, healthcare providers are
perceiving these behaviors indifference and lack of maternal investment in the baby,
impacting the way in which they interact with these women and how they include them in
medical care planning. And so the cycle continues, as these mothers feel further ostracized,
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judged, and discouraged from interacting with their infants (Cleveland, 2013; Cleveland &
Bonugli, 2014; Cleveland et al., 2016; Dimirci et al., 2015; Holbrook, 2015; Holbrook &
Nguyen, 2015; Howard, 2015; Howard, 2016; Jones et al., 2008; Mattocks et al., 2017;
Stengel, 2014; Stone, 2015; Suchman & Luthar, 2000).
Unfortunately, these recurring patterns of stigma and misconception become the
foundation of a socially-constructed barrier to early attachment development. The
combination of these challenges and deterrents results in reduced or complete lack of
visitation by the mother. This is detrimental to the mother and infant both independently
and as a dyad. The mother misses out on the opportunity to develop the attachment bond
and learn her child’s feeding and soothing preferences. Even when she does visit, her
interactions may be more depressed or anxious, which negative influences attachment,
bonding, and maternal confidence (Cleveland, 2013; Cleveland & Bonugli, 2014; Cleveland
et al., 2016; Dimirci et al., 2015; Holbrook, 2015; Holbrook & Nguyen, 2015; Howard, 2015;
Howard, 2016; Jones et al., 2008; Mattocks et al., 2017; Stengel, 2014; Stone, 2015;
Suchman & Luthar, 2000).
Without regular visitation and interaction with the mother, the infant is unable to
develop a secure attachment. Infants who lack secure attachment to their caregiver, the
mother in this case, are likely to be more irritable and cry more often than those infants
who have had the opportunity to develop that secure attachment. This increases the risk of
maternal stress which can be a potential trigger for substance use relapse and child abuse
or neglect. This cycle also prevents the utilization of the efficacious nonpharmacological
treatment approaches, all of which involve bonding and attachment development (Kim,
Fonagy, Allen, & Strathearn, 2014; Parolin & Simonelli, 2016; Suchman & Luthar, 2000).
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This comprehensive review of the literature has identified stigma as the biggest
inhibiting factor to bond-development between mother and baby. These psychosocial
factors and the corresponding benefits directly coincide with the principles of attachment
theory and the development of secure attachment with a caregiver. The following chapter
will thoroughly describe attachment theory, which is arguably the most renowned and
empirically-supported philosophy of human relationship development and explore the way
in which it relates to mothers and infants impacted by opioid use disorders.
CASE STUDY VIGNETTE
“Oh my God, I’m pregnant,” Kiana repeated to herself. An ultrasound revealed
that Kiana was about 12 weeks into her pregnancy. As Kiana lowered her head in utter
shock and disbelief, her eyes were immediately drawn to the track marks on her arms.
She quickly crossed her arms across her chest to conceal the proof that she’s “one of
those people.” Kiana silently wondered what the doctor thought of her as she stood in
front of her, wearing her neatly pressed white lab coat and expensive-looking black
leather flats.
Kiana’s mind started to wander into the foreshadowing of coming back to this
very hospital, six months from now, to give birth to her baby. She imagined the nurses
whispering soul-crushing comments about her being undeserving of motherhood. She
imagined being restricted from visiting her baby in the NICU, never getting to hold or
breastfeed her firstborn child. She imagined a child protective services worker taking
her baby from her arms while the staff stared at her with disdain. What was once a
lifelong dream has now become shrouded in fear.
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CHAPTER III: THEORETICAL FRAMEWORK
THE INTERSECTION OF PERINATAL OPIOID USE DISORDERS AND ATTACHMENT THEORY
Attachment theory focuses on the active, ongoing dynamics of interpersonal
relationships between human beings (Ainsworth, 1964). Psychoanalytic theory
concentrates on both healthy and maladaptive aspects of the human personality and
interrelationships. Attachment theory examines how we develop, internalize, and function
within these relationships (Bowlby, 1969). The theory of attachment is not just
philosophical in nature; there are several indications of neurobiology that support humans’
biologically-driven instinct to cultivate social relationships and interactions (Bowlby,
1957). Evidence shows that there are neurological connections to attachment theory,
including autonomic responses, which regulate heart rate and respiration, and
hypothalamic-pituitary-adrenal axis activity, which regulates stress (Bowlby, 1969). The
way in which a person experiences and internalizes attachment relationships is
neurologically catalytic. Furthermore, these memories become the hardwiring for
interpersonal connections and bonds (Applegate & Shapiro, 2005).
The empirical research uncovered has revealed that incorporating psychosocial
factors like breastfeeding, bonding, swaddling, cuddling, and family involvement improves
outcomes for infants with intrauterine opioid exposure. The literature also reveals that
additional psychosocial factors, like nurturing, supportive, stable homes with social and
family protective factors, provide further improved short- and long-term physical and
behavioral outcomes for these infants and their families. Each of these factors, though
individually beneficial, are all linked by an extremely significant common denominator.
They are all components of early attachment development.
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EARLY ATTACHMENT DEVELOPMENT
Early attachment development, though inherently a natural part of the child rearing
process, does require intentional interactions to occur between the baby and primary
caregiver. Bowlby defines attachment behavior as “any form of behaviour that results in a
person attaining or maintaining proximity to some other clearly identified individual who
is conceived as better able to cope with the world” (Bowlby, 1988, page 26-27). There can
be multiple attachment relationships between the infant and caregivers. Generally
speaking, the principal attachment figure is the mother, as she is the closest possible figure
to the birth itself. Subsidiary attachment figures include many other human beings who
interact with the infant. These figures are distinct from the primary attachment figure and
generally come in the form of playmates and substitute or short-term caregivers. These
figures, though they can be fleeting in nature, are also an integral part of the infant’s
attachment development. These figures exist outside of the safety nest created by the
primary attachment figure and provide the infant with the opportunity to explore and test
limits. At any point in which the infant becomes startled, hurt, or uncomfortable with the
subsidiary figure, he will instinctively seek out and retreat to the primary caregiver
(Bowlby, 1969).
Although there are certainly many instances where the non-maternal caregiver can
develop a strong primary bond with the infant, there are certain hormonal aspects of the
mother/infant relationship that make this bond occur more easily than with another
caregiver (Bowlby, 1969). Oxytocin, a powerful maternal hormone that acts as a bonding
neurotransmitter within the brain, is triggered within the mother when the infant engages
with or touches the mother (Klaus & Kennell, 1976). Eye contact between the infant and
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mother is most successful when within 12 inches of each other’s faces, as this is the
proximity in which an infant’s vision can clearly identify the mother’s face (Klaus &
Kennell, 1976).
The generation of oxytocin is just one of several hormonal bonding interactions that
occur within the mother/infant relationship. Klaus and Kennell (1976) identified and
described nine bonding interactions that are initiated by the mother, including touch, eye
contact, high-pitched voice, entrainment, time, lymphocytes (breastmilk nutrient), bacterial
nasal flora, odor, and heat. Klaus and Kennell (1976) also identified and described six
interactions that are initiated by the infant, including eye contact, cry, oxytocin (maternal
hormone), prolactin (hormone that encourages breast milk production), odor, and
entrainment. The increase in oxytocin is especially significant, as elevations in oxytocin
during bonding have been clinically shown to increase maternal euphoria, love, and
attachment to the infant (Klaus, 1998).
The importance of identifying the mother/infant relationship is not intended to
diminish the relevance or worth of other primary attachment figures, but rather to
emphasize the value of the maternal role regardless of the mother’s imperfections. This is
especially important to consider in the context of early attachment bonding between
mother/infant dyads impacted by opioid use disorders. The infant loves, desires, and
craves the mother no matter what. She is always important, and she is always needed.
Eye contact, physical contact, and verbal contact are all key elements of attachment
development between the mother and infant (Bowlby, 1977). To develop a strong
attachment bond, these activities must be consistent and reliable. Consistency is
predictable and inherently safe. During generally healthy, uncomplicated pregnancies,
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infants consistently receive nutrition through the umbilical cord without interruption.
Continuing that consistency in feeding while infants are still too small to provide for
themselves makes them feel safe (Bowlby, 1969). Once consistency is established, the
infants feel safe knowing that they are likely to receive the same response from the same
stimulus in the future. For example, infants know that they will be picked up and fed when
they cry (Bowlby, 1958).
Although there are several generalizable infant cues (i.e. cries when hungry), each
infant communicates differently than the other. Neonatal abstinence syndrome can play a
significant role in this attachment development and the way in which babies interact with
their attachment figures. Symptoms of NAS directly impact the way in which the baby eats,
sleeps, and cries. Infants initially utilize crying as a form of expression, but eventually
crying becomes the infant’s primary mode of communication with the mother (Bell &
Ainsworth, 1972; Bowlby, 1969). This is the infant’s primary and initial form of
communication with the mother. The infant’s cry initiates physiological responses within
the mother that induce breastmilk production. A mother can develop an incredibly strong
bond with her child as she learns to speak her child’s language (Klaus & Kennell, 1967 &
Tronick, 1989).
Holding the infant close to the chest fosters the feeling to security by mitigating the
infant’s fear of openness. The infant can safely and confidently explore the world around
him while feeling his mother within reach. Kangaroo Care, which originated in Bogota,
Colombia as a necessary means to compensate for shortage in equipment, involves skin to
skin contact in the critical care setting (Johnson, 2013). Kangaroo Care creates the
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desirable heat, scent, eye contact, touch, prolactin, oxytocin, as described by Klaus and
Kennell (1976).
Primary object sucking and clinging theory, also developed by Bowlby, asserts that
infants have an instinctual need to suck for nutrition and cling for affection. These needs
can be observed in infant behaviors when the infant exhibits the rooting reflex, which
refers to the way in which an infant seeks to find an object that touches his or her face,
especially near the mouth (Bowlby, 1969). Production of prolactin, a protein-based
bonding hormone that enables a mother to produce breastmilk, is triggered within the
mother when the infant engages with or touches the mother (Klaus & Kennell, 1967).
Though breastfeeding is not specifically required to develop a strong attachment bond, it is
ideal. Breastmilk has substantial nutritional benefits and contains lymphocytes and
docosahexaenoic acid (DHA) omega-3 fats (Klaus & Kennell, 1967; Andreas, Kampmann, &
Le-Doare, 2015). These nutrients promote neurodevelopment and reduce risk for affective
and developmental disorders (Liu, Leung, & Yang, 2014; Andreas et al., 2015).
THE IMPACT OF ATTACHMENT DEVELOPMENT ACROSS THE LIFESPAN
Bowlby posited that attachment development was a very black and white process:
either the attachment bond existed, or it did not. Ainsworth further elaborated upon this
concept and noted that there are specific intervals of attachment bonds that exist, which
she identified as attachment patterns, or styles, in the 1950s. Attachment patterns, or
styles, refer to infant behaviors that correlate to the way the infant experiences a
relationship with an attachment figure. Attachment patterns are developed in infancy and
are often strong indications of attachment pattern development in adulthood (Ainsworth et
al., 1978; Bowlby, 1969).
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ATTACHMENT PATTERNS IN INFANCY
Behaviors of attachment patterns in infancy are indicative of two things: the
behaviors through which the infant signals the mother’s attention and the infant’s
attainment and maintenance of the desired contact (Bell & Ainsworth, 1972). Based on
Ainsworth’s discoveries, infants ultimately develop one of three attachment styles: secure,
anxious-avoidant, anxious-resistant (Ainsworth et al., 1978).
Of note, it is important to consider four factors prior to making a determination
regarding a child’s attachment style: the location of the primary attachment figure, the
location of any subsidiary attachment figures, the physical environment, and the child’s
medical status. Any individual or combination of these factors can vastly impact the
behavior of an infant and may not be indicative of an attachment pattern (Bowlby, 1969).
Ainsworth identified one specific category for secure attachment and three distinct
categories of insecure attachment: anxious-resistant, anxious-avoidant, and disorganizeddisoriented (Ainsworth et al., 1978).
Securely attached infants will explore new surroundings with curiosity and interest
while occasionally looking back at the mother for support. This infant will develop strong
coping methods and adaptability to unfamiliar, uncomfortable situations. Secure
attachment is developed from two factors – the mother’s responsiveness to the infant’s
signals and the nature and quality of the time spent between the mother and the infant. A
mother who quickly picks up her crying infant, but then does not engage with him may
develop a weaker attachment bond with her child when compared to a mother who quickly
picks up her crying infant and then subsequently engages with him through eye contact
and speech. The quality of the time spent together is very important. This is not just about
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blindly responding to the child’s needs or enabling behavior, it’s about developing this
sense of closeness that makes the infant feel safe and secure. Allowing the child to “cry it
out” is an ineffective way to teach the infant to self-soothe. Infants develop a secure
attachment when engaged with primary attachment figures who are sensitive and loving
(Ainsworth et al., 1978; Bowlby, 1977). Other psychoanalytic disciplines may refer to
similar developmental outcomes as strong ego, basic trust (versus mistrust), mature
dependence, the true self, and internalization of the good object (Bowlby, 1977).
Infants who develop secure attachment with the primary caregiver(s) are generally
easier to soothe and exhibit less intense reactions to stressful stimuli, as they have been
forded with predictability and safety. The mutually experienced increase in oxytocin levels
fosters a close, loving bond as well as a decrease in occurrence of postpartum depression
(Klaus & Kennell, 1967). These infants are also more likely to explore their surroundings,
thus stimulating neurodevelopment and meeting developmental milestones (Bowlby,
1969).
Ainsworth identified three distinct categories of insecure attachment: anxiousresistant, anxious-avoidant, and disorganized-disoriented Anxious-resistant attachment
patterns are characterized by ambivalence toward attachment entities and surroundings.
Infants who develop anxious-resistant attachment styles will express significant emotional
distress when the mother leaves, only to ignore her upon engagement. The infant may pay
more attention to a subsidiary attachment figure than the primary. The infant’s behavior
toward the primary attachment figure seesaws from clingy to irate in response to
perceived neglect (Ainsworth et al., 1978; Mirick & Steenrod, 2016). Infants develop
anxious-resistant attachment when in the care of a primary attachment figure who is
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emotionally unavailable and unresponsive is experienced as insensitive and even rejecting
(Tracy & Ainsworth, 1981; Bowlby, 1969). Infants who develop anxious-resistant
attachment styles may end up developing transient attachment, which involves fleeting
interest in other humans and surroundings. In some cases, these infants stop attaching to
other humans and cultivate a self-centered, preoccupation with material objects, like
candy, food, and toys that provide them with pleasure and self-regulation (Bowlby, 1969).
The anxious-avoidant infant, on the other hand, does not show any particularly
protesting behaviors when the primary caregiver leaves the infant’s sight. However, when
the primary caregiver returns, this infant will simply show disinterest in her presence. The
infant’s response is neither angry nor excited in nature. Sometimes, specific efforts to
ignore the mother (such as turning the head away, using the arms to push off the mother)
are noticed. Infants develop anxious- avoidant attachment when in the care of a primary
attachment figures who is insensitive and inconsistent (Ainsworth et al., 1978; Mirick &
Steenrod, 2016).
The final attachment pattern, disorganized-disoriented, was not originally included
in Ainsworth’s literature. She identified and added this attachment style later in order to
accurately identify more extreme, inexplicable attachment behaviors. These behaviors
include perceived inability to function within the environment in the context of the
caregiver. Infants who develop disorganized-disoriented attachment are consistently
alternating between seeking attachment, attention, and bonding with the caregiver and
freezing, avoiding, and sometimes even lashing out against a caregiver without necessarily
having a specific invoking stimulus. These infants regularly exhibit contradictory behaviors
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due to inconsistent, unpredictable interaction with the caregiver (Ainsworth et al., 1978;
Mirick & Steenrod, 2016).
ATTACHMENT PATTERNS IN ADULTHOOD
On the other hand, infants unable to develop secure attachment struggle with
interpersonal relationship difficulties as adults. In the 1980s, Cindy Hazan and Phillip
Shaver extended this research to adults and found significant similarities in attachment
patterns between adults and children (Hazan & Shaver, 1994). As the child makes his way
into adulthood, he or she may exhibit behavioral and/or social difficulties (Flores, 2005).
They experience greater challenges with developing healthy platonic and romantic
relationships and engaging in intimacy with peers. Secure attachment development can be
hindered by abuse, neglect, trauma, and poor caregiver consistency and reliability. Adults
who struggle with attachment development may exhibit overwhelming, maladaptive,
irrational behaviors as a way of demanding love and attention while simultaneously
playing a resentful, extreme caretaker role. In rare cases, sociopathology can arise from
extreme attachment issues (Bowlby, 1977).
Infants who developed secure attachment to a primary caregiver generally
transition into becoming well-adjusted adolescents and adults and have the ability to fulfill
the natural human desire to develop trusting relationships. Securely attached adolescents
and adults are cooperative, empathetic, and easily engaged with others. Well-adjusted
adults are also characterized by having established coping skills and are successful with
affect regulation (Bowlby, 1977). Research indicates that infants who were breastfed, and
engaged during breastfeeding, are less likely to internalize feelings of anxiety, depression,
and other somatic symptoms as adults (Liu et al., 2014).
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Three distinct categories of insecure attachment in adulthood: dismissive-avoidant,
anxious-preoccupied, and fearful-avoidant. Dismissive-avoidant adults often feel as though
achieving and maintaining relational independence is more important than developing
closer, more intimate relationships. They have a strong self-perception and a lower value
perception of others (Hazan & Shaver, 1994).
Anxious-preoccupied adults are characterized by opposite relational worldviews.
They perceive themselves to have a lower self-value, while others are perceived more
positively with a higher value. These adults find that they crave extremely intimate
relationships with others, and often become disheartened when this need is not met
(Hazan & Shaver, 1994).
Fearful-avoidant adults experience a combination of the dismissive-avoidant and
anxious-preoccupied attachment patterns. Adults with this attachment style are often
unsure of how they want to experience relationships and are further confused by how to
determine or achieve their desired relational goal. This fluctuating and alternating
approach to relationships with others can often inhibit the creation of healthy, stable
relationships in general.
Life experiences that contribute to fearful-avoidant adult attachment styles can
often be associated with complex trauma (Hazan & Shaver, 1994). When the need for selfregulation, security, and predictability is not met, the insecurely attached person looks to
compensatory measures. This unconscious search for compensatory measures can
manifest in several different ways, including addiction. The addiction, however, ultimately
provides the opposite of self-regulation, security and predictability. It is an attempt to selfrepair that always fails. It is rare to meet a person with substance dependency who does
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not also have some form of attachment trauma history (Flores, 2005; Parolin & Simonelli,
2016).
MATERNAL/INFANT ATTACHMENT DEVELOPMENT IN THE HOSPITAL SETTING
As previously mentioned, early attachment development, though an inherently
natural part of the child rearing process, does require intentional interactions to occur
between the baby and primary caregiver. These interactions are especially challenging in
the hospital setting, which can act as a barrier to attachment itself. Hospitals are generally
sterile, uncomfortable environments where medical treatment and sanitation is, logically,
prioritized over relaxation and coziness. In many cases, curtains between patients are the
extent to which privacy exists. There are limited options for personalized bonding or free
range of motion, pushing away from an attachment-fostering atmosphere.
As empirical evidence continues to support the significant relationship between
early attachment bonding and physical, mental, and interpersonal health outcomes,
researchers are beginning to explore new approaches to cultivating these bonds. For
example, an adaption of child-parent psychotherapy (CPP), an attachment-based
psychotherapeutic intervention, is currently being piloted in a NICU setting in a Californiabased study. This pilot program aims to evaluate the efficacy of this NICU-specific adaption
of CPP in improving infant/parent bonds (Lakatos, Matic, Carson, & Williams, 2019).
These types of studies, although incredibly important and vital to improving
infant/parent relational outcomes, fail to address the specific needs of mothers and infants
impacted by opioid use disorders, a remarkably stigmatized, vulnerable population. The
way in which a mother develops a relationship and bonds with her infant with NAS has its
own unique challenges. Infants being treated for NAS also have difficulties communicating
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effective cues to their caregivers, making it more challenging than usual to console them.
The sound of their cries, for example, is very different than other newborns. Their cries are
louder and higher pitched. They are also much more difficult to console (MaGuire et al.,
2016).
Though the attachment styles identified by Ainsworth have clear differences, they
may be difficult to appropriately identify in the baby being treated for NAS. For example,
because symptoms of NAS resemble behaviors linked to insecure attachment, such as
irritability, agitation, and excessive crying, it may be difficult to identify how the infant’s
attachment to the mother is developing during NAS treatment. Even if a mother visits her
infant every day to support a secure attachment, the benefits of her efforts may not be
evident until after the baby’s course of treatment is finished. Representations and
relationships with attachment figures in childhood perseverate into adulthood.
Consequently, the internalization of these relationships ultimately becomes the self-model
(Bowlby, 1977). By diminishing the opportunity to provide education and foster healthy
attachments between these mothers and their infants, providers are simultaneously, and
drastically, increasing risk of harm and perpetuating this cycle. The need for an evidenceinformed approach like the PARTNER model is evident.
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CHAPTER IV: METHODOLOGY
PURPOSE AND SIGNIFICANCE
The purpose of this dissertation is to develop an original, multidisciplinary practice
model for providers working with mothers and infants impacted by opioid use disorders. A
thorough review, synthesis, and critical analysis of the literature has revealed that there
are several treatment approaches for pregnant and postpartum women with opioid
disorders, as well as infants diagnosed with NAS. The literature review has also revealed
that maternal engagement, support and care, all of which are empirically shown to improve
outcomes for both the mothers and infants themselves, are consistently being obstructed
by barriers to care. The most commonly identified barriers to achieving these improved
outcomes are sociocultural constructs including stigma, judgment, and exclusion. These
psychosocial factors do not coincide with the disease-model approach of medicine and are
substantially hindering the delivery of quality, unbiased care.
Effective treatment approaches and barriers to care have been clearly identified in
the existing literature, but a missing piece to this complex puzzle remains: how can
providers work with pregnant and postpartum women and their infants in a way that
reduces stigma and fosters attachment? The PARTNER model bridges this gap in the
literature in an innovative, practical, and approachable way. It embraces the humanistic
side of this delicate relationships that does not exist in the medical treatment models
guiding healthcare practices. The current literature, as well as this identified gap in the
literature, support the need for a practice model that provides guidelines for providers. The
PARTNER model has been designed to guide providers in providing ethical, humanistic,
attachment-focused care to mothers and infants like Kiana and William.

60

PRACTICE MODEL AND COMPOSITE CASE STUDY DESIGN
The PARTNER model takes all the aforementioned factors into consideration and
equips healthcare providers with the education and guidance needed to not only create a
partnership between the mother and the infant, the mother and providers as well. The
PARTNER model is comprised of seven key elements of attachment-focused care, including:
1. Person-Centered
2. Attachment-Informed
3. Risk Reduction
4. Trauma-Informed
5. Neutrality
6. Empowerment
7. Reinforcement
This model has been designed to provide guidance to providers working pregnant
and postpartum women with opioid use disorders. “Providers” include licensed
professionals working in a healthcare setting including, but not limited to, physicians,
nurse practitioners, physician assistants, psychologists, registered nurses, and clinical
social workers (Code of Federal Regulations, 2012).
This model has been developed based on the review, synthesis, and critical analysis
of the current literature along with the integration of relevant practice knowledge, theory,
and research. Each element is derived from evidence-based practices with modifications to
meet the unique needs of this unique population. There are no other constraints in terms of
gender identity, race, age, or socioeconomic status. However, there are recommendations
for consideration of these factors incorporated into the model.
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Composite case vignettes, informed by clinical experience and empirical literature,
have been incorporated throughout this dissertation. These case vignettes tell the story of
Kiana, a 23-year-old black, heterosexual, cisgender woman with a perinatal opioid use
disorder. Pertinent elements of Kiana’s history have been integrated throughout the
literature review, illuminating and connecting her story to the concepts that set the
foundation for the PARTNER model. Kiana’s story continues after the introduction of the
PARTNER model, picking back up from where it stopped at the end of the literature review.
The story of Kiana’s journey through pregnancy and the birth of her baby, William,
brings life and connection to each element of the PARTNER model. The PARTNER model
has been specifically designed with patients like Kiana and William in mind, whose story is
similar to many of the women and babies impacted by perinatal opioid addiction.
Identifying areas of antiquation and integrating strengths-based interventions emphasizes
the importance of promoting attachment between a mother and her infant, provides a
person-centered framework from which to work, and fosters insight into and mitigation of
socially-constructed barriers that deepen the divide between “us” and “them.”
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CHAPTER V: PRACTICE MODEL AND CASE STUDY
INTRODUCTION TO THE PARTNER MODEL
This chapter will provide a layout of the PARTNER model including an overview, key
elements, significance, and application to practice. The following chapter will include a case
study that provides examples of how each of the elements should be integrated into
healthcare provider practice. The PARTNER model is comprised of seven key elements of
attachment-focused care, including:
1. Person-Centered
2. Attachment-Informed
3. Risk Reduction
4. Trauma-Informed
5. Neutrality
6. Empowerment
7. Reinforcement
All of these elements are intended to be integrated simultaneously and seamlessly
into care. The model emerged from an understanding of risk factors for opioid use
disorder, barriers to prenatal/postnatal care, and ways to address these issues with a focus
on fostering attachment not just by developing a partnership between mother and baby,
but also between mother and the care providers. Each element has a common goal of
educating, reducing stigma, and fostering attachment. These components can certainly be
applied to anyone with a history of addiction, but this model is specifically designed for
pregnant and postpartum women currently struggling with addiction, as it specifically
addresses the unique needs of this population as uncovered in the literature.
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THE PARTNER MODEL IN ACTION
Throughout the PARTNER model analysis, vignettes from Kiana’s composite case
study are incorporated to illustrate how the elements of the PARTNER model are
implemented in practice. To reintroduce Kiana, she is a 23-year-old black, heterosexual,
cisgender woman with a perinatal opioid use disorder. Kiana currently lives in Philadelphia
with her mother and two younger sisters and works long, late-night hours a restaurant. She
has several risk factors linked to substance use disorders, including a family history of
alcohol abuse, mental illness, and domestic violence, all of which contribute to Kiana’s ACE
score of 8/10. Kiana has also been diagnosed with depression and has experienced sexual
violence in adulthood.
Kiana was first introduced to opiates at age 20, when she was given a prescription
for Percocet after getting into a car accident. Without having any education on opioid risks,
she took the Percocet prescription every day for two months. Unfortunately, a handful of
missed opportunities helped to create a pipeline to addiction. Kiana never got
psychoeducation on the risk of opioids or an evaluation for opioid dependency. Kiana was
met with stigma and judgment rather than support and unbiased care. It was only a matter
of weeks before Kiana became physically dependent and behaviorally addicted to opioids.
Eventually, Kiana transitioned from Percocet to heroin.
Three years after being introduced to opiates, Kiana experienced her first overdose.
She was treated with NARCAN and brought to the hospital for an evaluation and workup. It
was during this emergency department visit that Kiana found out she was 12 weeks
pregnant. Kiana’s story continues from here, at which time she is treated by providers who
are working from the PARTNER model approach. By integrating the PARTNER model
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approach into their practice, Kiana’s healthcare providers are able to meet Kiana where she
is, identify her strengths, and help her develop an early attachment bond with her baby by
meeting her where she is and providing her with person-centered, unbiased, ethical
medical care.
P: PERSON-CENTERED
The first element of the PARTNER model is person-centered. A person-centered
approach is characterized by the establishment of equal partnership between the provider
and the patient that is rooted in genuine empathy for individually lived experiences. Equal
partnership is the foundation of the person-centered approach. It requires providers to
view the patient as an individual person with individual needs, leaving behind the one-sizefits-all mentality. This approach is vital to this practice model, as it supports the
overarching goal to educate, destigmatize, and foster attachment as equal partners in
planning rather than from an imbalanced power approach. The provider and patient still
have their unique roles within the relationship, but it is more collaborative in nature than a
traditional directive healthcare approach. When working from this framework, providers
act as guides or coaches in informed healthcare decision-making. This also requires
providers to acknowledge the power dynamics that exist within the patient/provider
relationship, which can often act as barriers to developing this equal partnership. The
benefits of creating this partnership can also surpass pregnancy, as it can open an ongoing
doorway to developing and maintaining a safe, comfortable relationship with health care
systems in general.
Person-centered care also requires providers to respect and appreciate the patient’s
world, free from judgment or stigmatization. The empathy involved in person-centered
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care goes beyond understanding feelings; it requires a capacity for deeper understanding
and acceptance of the patient’s lived experiences from the patient’s individual life
paradigm. Through this approach, providers can capture a patient’s true narrative by
allowing the patient to guide and process the narrative themselves. It is a holistic approach
that requires providers to meet the patient’s needs in a way that is applicable to the
patient’s uniquely lived experiences.
CASE STUDY VIGNETTE
Kiana was brought to the hospital after overdosing on heroin. She is laying on a
stretcher in an emergency department room, feeling ashamed, embarrassed, and
completely overwhelmed. She has just been told that she is pregnant, approximately 12
weeks’ gestation. Per hospital protocol, Kiana is admitted to the maternal/fetal
medicine unit for withdrawal monitoring and treatment, which involves medicationassisted treatment initiation. Allison, a licensed clinical social worker, has been
consulted to meet with Kiana and complete an initial assessment using the PARTNER
model to guide her approach.
Allison knocks on the door, asking permission to enter the room and sit in the
open chair next to Kiana’s stretcher. Allison introduces herself and reviews her role as
the perinatal clinic social worker. Allison explains to Kiana that she is here to meet
with her, provide support, and talk through some questions to determine how she can
be the most helpful. Allison explains that she is going to ask Kiana several questions.
“Kiana, if at any point you feel overwhelmed or uncomfortable, just let me know. I
know you’ve had a really tough day, so we will move at whatever pace feels the most
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comfortable for you. We can take a break or stop at any time. Does this sound okay
with you?”
At this point in the interaction, Kiana feels anxious and ashamed. However,
Allison’s empathic understanding approach helps to put her at ease. Allison is using a
person-centered approach to engage Kiana and lay the groundwork for the
development of an equal partnership between Kiana and her healthcare providers. She
is showing respect for Kiana’s physical and mental space by asking for permission to
enter the room and putting the control of the assessment pace in Kiana’s hands.
Throughout the assessment, Kiana reveals clinically significant aspects of her
life that have been empirically identified as risk factors for opioid dependency. Allison
is engaged in active listening, providing empathic validation while assessing for
Kiana’s needs. Allison also discusses pregnancy options (parenting, adoption, and
termination) without making any assumptions, practicing from a collaborative, rather
than authoritative, approach. Kiana shares that she would like to move forward with
the pregnancy and parent her baby but does not know where to start.
Allison introduces the opportunity to help connect Kiana to an ob/gyn for
prenatal care and medication-assisted treatment programs, discussing all of the
options with her. Kiana expresses interest in initiating this type of treatment. Allison
asks Kiana, “We’ve talked about a few different programs. Based on what you’ve told
me about you, I think the buprenorphine clinic that specializes in perinatal health
would be great for you. What do you think?” Again, by taking this approach, Allison
practicing from a collaborative, rather than authoritative, approach. She is creating
an equal partnership with Kiana and is giving her autonomy in evaluating her
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healthcare decisions. Kiana agrees to starting buprenorphine medication-assisted
treatment management with the perinatal addiction clinic. Allison provides a warm
handoff to both the perinatal addiction clinic and outpatient ob/gyn clinic teams.

A: ATTACHMENT-INFORMED
The second element of the PARTNER model is attachment-informed. An attachmentinformed approach involves integrating support, psychoeducation, and engagement that
fosters relationship building between providers and the patient, as well as the patient and
the baby. The empirical research uncovered has revealed that incorporating psychosocial
factors like breastfeeding, bonding, swaddling, cuddling, and family involvement improves
outcomes for infants with intrauterine opioid exposure. The literature also reveals that
additional psychosocial factors, like nurturing, supportive, stable homes with social and
family protective factors, provide further improved short- and long-term physical and
behavioral outcomes for these infants and their families. Each of these factors, though
individually beneficial, are all linked by an extremely significant common denominator.
They are all components of early attachment development.
Although there are several generalizable infant cues (for example, crying when
hungry), each infant communicates differently than the other. Neonatal abstinence
syndrome can play a significant role in this attachment development and the way in which
babies interact with their attachment figures. Symptoms of NAS directly impact the way in
which the baby eats, sleeps, and cries. Infants initially utilize crying as a form of expression,
but eventually crying becomes the infant’s primary mode of communication with the
mother. This is the infant’s primary and initial form of communication with the mother.
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The infant’s cry initiates physiological responses within the mother that induce breastmilk
production. A mother can develop an incredibly strong bond with her child as she learns to
speak her child’s language. Eye contact, physical contact, and verbal contact are all key
elements of attachment development between the mother and infant. To develop a strong
attachment bond, these activities must be consistent and reliable. Consistency is
predictable and inherently safe. This is an important consideration when working from an
attachment-informed framework to foster partnership between the mother and her baby,
as well as the mother and her providers.
CASE STUDY VIGNETTE
Kiana presents to the ob/gyn clinic office for her first prenatal care visit. Kiana
looks around and sees several other pregnant women in the waiting room. Kiana
wonders to herself, “Do I even belong here? Do I even deserve to be a mom?” Kiana
timidly approaches the front desk to start the check-in process. Terrie, the ob/gyn
practice manager, greets her with a warm smile.
“Hi Kiana, thank you so much for coming to see us today. How are you feeling?”
“I’m okay, thanks,” Kiana responds. Kiana still feels hesitant but notices a sense of
relief. “We have some paperwork for you to fill out,” Terrie says. “Take your time, no
rush. If you have any questions, just let me know. I’m here to help.” Terrie
acknowledges the imbalanced power dynamic that exists between healthcare
providers and patients. She is engaging Kiana from an attachment perspective,
utilizing a nurturing, supportive approach.
After her paperwork is completed, Kiana is greeted by Beth, one of the ob/gyn
office nurses. Beth walks Kiana back to the patient room and completes her vitals. Beth
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asks Kiana if she has any questions or concerns that she would like to address during
her visit today. Kiana has more questions than she can count, but she quietly responds,
“I’m not really sure.” Beth recognizes that this is a stressful, intimidating situation for
Kiana. To normalize Kiana’s feelings, Beth responds, “That’s okay. I don’t know any
new moms-to-be who know exactly where to start. There’s so much to think about!
Why don’t we start with what to expect for this visit?” Beth provides Kiana with an
overview of the first prenatal care visit. Like Terrie, she is engaging Kiana from an
attachment perspective, utilizing a nurturing, supportive approach.
Shortly after Beth leaves the room, Dr. Ziegel knocks on the door, asks
permission to enter the room. “Hi Kiana, it’s so nice to meet you. My name is Dr. Ziegel,
but everyone calls me Jenny,” she says. During Jenny’s evaluation and assessment, she
asks Kiana some questions about her opioid use disorder history and the newly
initiated medication-assisted treatment management. Kiana states has been working
well for her thus far, but Jenny notices Kiana appears visibly upset. Jenny asks, “What’s
going through your mind, Kiana?” Kiana replies, “What’s going to happen to my baby?”
Jenny takes the time to answer all of Kiana’s questions. Jenny explains the
different ways in which opiates and buprenorphine interact with the baby in utero,
reassuring Kiana that the baby is safer with the medication assisted treatment. Jenny
provides education on neonatal abstinence syndrome, explaining the diagnosis and
treatment process. Jenny also provides education on mandated reporting laws,
explaining that the hospital is legally required to notify child protective services of any
unprescribed opioid use during pregnancy. Jenny also emphasizes the impactful role of
maternal engagement and attachment bonding activities in the NAS treatment
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process. By doing this, Jenny is laying the groundwork for early attachment bond
development. Jenny is thoroughly explaining all aspects of the perinatal opioid
dependency, but discusses these sensitive topics using supportive, unthreatening,
approach. The goal is to foster inclusion and partnership rather than fear and
disconnection. Jenny is letting Kiana know that she is not only deserving of being a
mother, but she is needed and an important part of the baby’s treatment team.
R: RISK REDUCTION
The third element of the PARTNER model is risk reduction. Engaging in a risk
reduction approach involves working together, with the patient, toward the establishment
of safety and improvements rather than perfection. Risk reduction involves realistic,
sustainable goal setting with realistic, individualized expectations, as well as identifying
and mitigating barriers to achieving these goals. Goal-setting can include, and is not limited
to, discussions surrounding treatment, parenting, child protective services. These goals can,
and likely will, evolve throughout the pregnancy and postpartum periods. By guiding the
patient through the thought process of goal-setting, providers can help set the patient up
for successful outcomes. A patient’s goals should be augmented by psychoeducation to
ensure informed decision-making. This is especially important when discussing harm
reducing practices in blood borne infectious diseases and overdose prevention.
Again, risk reduction works toward establishing safety and improvements rather
than perfection. This is important for the provider to consider as well, not just the patient.
Research shows that providers can expect some degree of noncompliance and
inconsistency in care planning with people who suffer from addiction (Tkacz, Severt,
Cacciola, & Ruetsch, 2011). Providers should respect, acknowledge, and appreciate any
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preexisting and ongoing challenges of a patient’s lived experiences. Providers should also
respect patient’s right to disclose sensitive information and accept that patient may not
always be forthcoming, especially given the context of the heavy stigma surrounding
pregnancy and addiction. Maintaining realistic expectations supports the person-centered
approach and reduces occurrence of stigma, as it recognizes and respects each individual
patient’s abilities, strengths, and needs. A patient’s care planning noncompliance is not
indicative of flawed character or moral failing and should be approached accordingly.
Identifying and mitigating barriers to care is an essential component of this process,
as barriers to care often contribute to health care noncompliance. Barriers to care, such as
lack of transportation, medical insurance, housing, and other resources are significantly
more likely to be lost to care than those patients who have their basic needs met. In cases
where barriers do not have an identifiable or viable solution, providers should consider
referring out to external agencies for ongoing case management support. It may not be
possible to mitigate all barriers to care, but again, the aim should be toward improvement,
not perfection.
CASE STUDY VIGNETTE
Kiana returns to the ob/gyn office next prenatal appointment. Kiana is greeted
by her doctor, Jenny, with a warm smile. “It’s so great to see you again, Kiana. Thank
you for coming to see us today.” After her prenatal exam and labs are completed,
Kiana anxiously shares with Jenny that she experienced a brief relapse last week.
Kiana is terrified and embarrassed to admit this, as she does not want anyone to think
she does not love her baby. However, the consistently nonjudgmental engagement
Kiana experiences with her healthcare team helps her feel more comfortable sharing
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this. Jenny acknowledges and commends Kiana for her bravery in sharing this
information.
Jenny is well-versed in opioid use disorders and understands that relapse is an
anticipated, commonly experienced aspect of the recovery process. Jenny approaches
her practice with an aim for improvement, not perfection. Jenny also practices from a
disease-model approach, making sure to emphasize to Kiana that this relapse is part of
the process, not a moral failing or character flaw.
Jenny provides Kiana with some brief supportive counseling, motivational
interviewing techniques, and psychoeducation on the opioid addiction recovery
process. Jenny also reviews some additional risk reduction information, including
education about needle sharing and needle exchanges. Her goal is to keep Kiana and
her baby as safe as possible. Jenny also asks some questions to assess for access to basic
needs and barriers to care, uncovering that Kiana is having a hard time navigating
WIC program benefits. Jenny offers to send a referral to local non-profit agency that
provides case management supports to pregnant women with opioid use disorders,
which Kiana accepts.

T: TRAUMA-INFORMED
The fourth element of the PARTNER model is trauma-informed. Practicing from a
trauma-informed approach involves the establishment safety between the patient and the
provider through connection and authenticity. Safety is the cornerstone of attachment
development. Creating a sense of basic safety is necessary for patients to feel comfortable
with engaging with their healthcare providers. Successfully establishing safety is heavily

73

dependent on the patient’s individual trauma history and attachment style, but providers
can continuously work toward creating physical and emotional safety within the
patient/provider relationship (Sanders & Hall, 2018). Patients need to feel physically safe
within the immediate space between themselves and the providers. Patients also need to
feel emotionally safe within the patient/provider relationship. Emotional safety can be
established through the use of clear, calm communication, as well as mindfulness of verbal
and non-verbal language. Patients need to feel safe simply being themselves.
To develop this kind of close relationship with a patient, it is ethically imperative
that the relationship is authentic, genuine, and trustworthy. Providers should take the time
to learn their patient’s preferences, strengths, needs, and values and integrate these factors
into care planning. This approach also requires implementation of cultural considerations,
which aids in solidifying the respect for individual life and identity. Within the context of
this authentic relationship, patients learn to trust their providers, which results in stronger
engagement and relationship-building. Establishing an authentic relationship promotes
transparency, respect, and humane care.
CASE STUDY VIGNETTE
Kiana presents to the hospital for her scheduled induction of labor. Kiana first
meets with her nurse, Kerry, who notices that Kiana is visibly nervous. Kiana is looking
down at her hands, fidgeting, and avoiding eye contact. Kerry greets Kiana with
warmth, kindness, and reassurance. Kerry understands the importance of building an
authentic, genuine rapport with Kiana to foster trust and safety.
Kerry introduces herself and utilizes light, appropriate humor to help put Kiana
at ease. “The labor induction process can take several hours sometimes. If you get
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bored and I’m not in another patient’s room, I’d be happy to provide you with a special
‘Karaoke Kerry’ performance.” Another nurse, Bobbi, chimes in and says, “Trust me,
you don’t want to hear any of that – ‘Karaoke Kerry’ is not as talented as she thinks she
is.” Kerry and Kiana share a laugh together, which helps Kiana feel more comfortable
and connected to her unfamiliar surroundings.
Kerry begins with the routine intake evaluation, starting with less stressful
screening questions, like smoking cigarettes. “Kiana, do you smoke cigarettes or use
any tobacco products? If so, how often?” Kiana quietly responds that she does smoke
cigarettes, about four to five times per week. Kerry responds by offering to get Kiana a
nicotine patch to use during her admission, which Kiana declines for now. Kerry tells
Kiana, “If at any point you feel like you need one, just let us know. The labor induction
process can be stressful and take a long time. I’m here to support you through this
process, so please do not hesitate to use the call bell to let me know if you change your
mind. Kerry is aware that hospitalizations come with several stressful stimuli that can
contribute to traumatic experiences. Kerry reminds Kiana throughout her labor
induction, “Whatever you need, I’m here for you.”
Kerry moves forward with the intake process and reviews Kiana’s medicationassisted treatment management. Kiana still feels a bit nervous, but Kerry’s warmth
and humanistic approach to care helps to put Kiana at ease. Kerry answers all of
Kiana’s questions with transparency. This is especially important in regard to
toxicology screenings, NAS monitoring, and child welfare involvement. Kerry is also
sure to ask if there will be any visitors who are unaware of Kiana’s recovery. Kiana
explains that her mother and boyfriend are aware, but her two younger sisters are not.
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She asks that no one mentions this in front of them. Kerry assures Kiana that this
information will be noted in her chart and included in all handoffs, further fostering
safety and respect.

N: NEUTRALITY
The fifth element of the PARTNER model is neutrality. Neutrality is characterized by
fully objective, nonjudgmental care and is maintained through self-awareness and selfevaluation. All patients have the right to objective healthcare that is free from judgment,
prejudice, and bias. This is especially important for providers working with pregnant and
postpartum women with opioid use disorders, as the stigma they experience is amplified.
This marginalized group of postpartum women endure all the standard postpartum
challenges while simultaneously drowning in disapproval and judgment that is so brazenly
conveyed by others, especially hospital staff members. There is concrete, measurable
weight and influence in the way in which a patient believes he or she is perceived by a
person in an authoritative position. Providers are inherently viewed as powerful.
Internalized feelings of guilt and shame are amplified by the judgment and stigma imparted
on them by providers. Providers have an ethical responsibility to develop and maintain
self-awareness to mitigate implicit bias and countertransference. When faced with any
internal challenges that could compromise the integrity and neutrality of their work,
providers should seek consultation.
CASE STUDY VIGNETTE
After several hours of labor induction, Kiana gives birth to a healthy baby boy
named William. William was immediately placed on Kiana’s chest , initiating early
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attachment bonds straightaway from birth by promoting skin-to-skin Kangaroo care.
Kiana’s nurse, Bobbi, taught her how to swaddle the baby and provided her with
breastfeeding education and support. Kiana and William are being given objective,
unbiased treatment that all mothers and babies deserve.
Kiana’s providers are mindful of their language choice. During morning rounds,
the team identifies that Kiana is on medication-assisted treatment, which requires an
extended admission for William to monitor for NAS symptoms. They never refer to
Kiana as a “drug mom” or “Subutex mom.” They never refer to William as a “drug
baby” or a “Subutex baby.” The team prioritizes destigmatizing, person-first language.
The team consistently respects Kiana’s wishes in regard to who can be present during
sensitive discussions.
The postpartum hospital social worker, Danielle, stops by Kiana’s room to
introduce herself and congratulate Kiana on the birth of her baby. “Hi Kiana, my name
is Danielle. It’s so nice to finally meet you. I’m one of the postpartum social workers
that works with Allison. I’m not sure if you remember her; you met her a few months
ago.” Kiana remembers Allison, the social worker who helped her get connected to the
perinatal addiction medicine and ob/gyn clinics. Kiana remembers Allison’s kind,
nonjudgmental demeanor. Through the use of warm handoffs, Kiana’s provider team is
able to preserve and build upon these connections and relationships.
Danielle continues, “Allison is off until Wednesday, but she let me know you
were scheduled for induction this week. She’s so bummed about missing you, but she
will be back before you leave. I don’t want to interrupt your bonding time with William
now, so I will come back tomorrow. Is there any particular time that you’d prefer?” By
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integrating these aspects of neutrality and connection into her care, Kiana’s
healthcare providers have created a safe space where she can truly enjoy her first
moments of motherhood with humanity, dignity, and respect, free from bias and
judgment.
E: EMPOWERMENT
The sixth element of the PARTNER model is empowerment. Empowerment is
characterized by the promotion of self-worth and autonomy. To truly empower patients,
providers first need to recognize and break down influences of stigma to promote
worthiness of self. The stigma of addiction as a moral failing can permeate into the patient’s
belief in their deservingness of motherhood. At the most basic level of humanity, the
patient still has the right to be a person.
The way in which providers work toward creating a sense of empowerment in
patients needs to be individualized and person-centered, especially in the context of
perinatal opioid use disorders. In order for patients to experience a sense of
empowerment, providers should provide proactive psychoeducation and tools to promote
autonomous and informed decision-making. This is especially important in the
transparency mandated reporting laws and policies, as well as potential child welfare
outcomes. The education, support, and encouragement needs to be applicable and
appropriate for each individual patient’s situation and circumstances. For example, the
ability to safely breastfeed the baby may not be possible for some patients depending on
active opioid use and/or contraindicated medications. In this type of situation, providers
should identify other ways to empower the patient without shaming or diminishing selfworth.
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CASE STUDY VIGNETTE
The following day, Danielle returns to meet with Kiana. Danielle is aware that
although she briefly met with Kiana yesterday, she needs to continue to establish
rapport with Kiana. Danielle engages with Kiana, giving Kiana the opportunity to
process her feelings about her pregnancy, labor, and first childbirth experience.
Danielle connects with Kiana over the baby’s name, sharing that her best friend’s name
is William.
Danielle’s assessment covers several areas, including evaluating for access to
basic needs, infant preparedness, social supports, and postpartum/newborn
psychoeducation. Danielle also reviews clinical assessment information, including
mental health history, postpartum depression screening, intimate partner violence,
substance use history, and mandated reporting laws. Kiana is already aware of
mandated reporting laws and required child protective services report. She remembers
having this discussion with Jenny during one of her prenatal care visits.
Kiana shares with Danielle that she feels well-prepared for this process, but she
is still afraid. Kiana discloses feelings of shame and guilt. She reveals to Danielle, “I feel
like I’m a bad person and a bad mom. William deserves better than me. It’s my fault
that he has to go through withdrawal. I know what that feels like, and I can’t believe
my mistakes are causing my baby to feel that way. I don’t want anyone to think I don’t
love my baby.”
Danielle recognizes Kiana’s addiction and child protective service involvement
is not new information, but this information has new context now that the baby has
been born. Danielle gives Kiana the space to talk through and process these feelings,
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while utilizing supportive counseling and cognitive-behavioral techniques to work
toward mitigating the cognitive distortions. Danielle works together with Kiana to
reframe her thoughts, highlighting Kiana’s growth, protective factors, and resilience.
Most importantly, Danielle reassures Kiana that she is an integral part of
William’s care team, reminding her that maternal engagement and early attachment
bond development is scientifically shown to positively impact NAS treatment outcomes
and early childhood development. By doing this, Danielle is working toward restoring
Kiana’s self-worth and empowering her to be an active participant in William’s care.

R: REINFORCEMENT
The seventh and final element of the PARTNER model is reinforcement.
Reinforcement is characterized by repetition and consistency. Patients regularly do not
retain most of the information they receive from their healthcare providers. This is
especially evident in the setting of stressful stimuli, which directly impacts memory
function. Stressful stimuli can also activate maladaptive self-defense mechanisms, selfdestructive cognitive distortions, and denial. When faced with unpleasant circumstances,
patients may also subconsciously pick certain pieces of information to remember or ignore
to appease the ego. Providers should be willing to review education and information in
various formats to meet their patient’s needs. The process of repetition should be
approached with patience, anticipation, and empathy.
Providers should also be providing consistent information with a united approach
to care. This practice is integral to this model, as it fosters trust and reduces ambiguity.
Consistency is especially important when discussing sensitive topics including infant
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withdrawal monitoring protocol, NAS, and child protective service involvement. Providing
consistent information is not only ethically imperative, but it aids in reducing ambiguity for
the patient. Consistency can be cultivated through wraparound support approaches and
warm handoffs to ensure continuity of care.

CASE STUDY VIGNETTE
It is the discharge day for Kiana, but William’s admission continues for NAS
monitoring. Kiana knows this day was going to come, but it still doesn’t feel real. After
Kiana is formally discharged from the hospital, William is transferred to the nursery,
where he will remain for at least the next two days. William may need to stay for
longer, depending on his withdrawal symptoms. Kiana returns to her mother’s home to
unpack her bags and take a shower but returns to the hospital shortly afterward to
stay by William’s side. When Kiana arrives at the nursery, she feels overcome with
doubt, asking herself, “Do I even belong here? Do I even deserve to be a mom?”
Moments after entering the nursery, Kiana is greeted by William’s nurse, Steph.
“Hi Kiana, my name is Steph and I’ll be taking care of William with you today. You’re
just in time for rounds! This is Robert, the attending pediatrician.” Robert turns to
Kiana, extending his arm and gesturing to Kiana to come join the discussion. Steph and
Robert are aware of how intimidating this environment can feel. They know Kiana has
been educated on the benefits of early attachment bonding, but they are reinforcing
this message to engage her as an active, important member of the baby’s treatment
team.
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Steph, Robert, and other members of the team include Kiana in the care
planning discussion during rounds. They review William’s newborn delivery notes and
his treatment plan, consistently using person-first, destigmatizing language. Robert
reviews NAS scoring protocol with Kiana, showing her the Modified Finnegan NAS
Scoring Sheet as they discuss William’s scores over the past 24 hours. Robert knows
Kiana has been educated on the NAS scoring process. However, he also understands
the benefit of repetition, especially considering the significant stimuli exposure Kiana
has experienced over the past few days.
Steph reviews Kiana’s breastfeeding plan, pausing every so often to create the
opportunity for equal partnership discussion and questions. Feeling comfortable as a
member of the care team, Kiana asks, “Is it definitely safe for me to breastfeed with the
Subutex?” Steph knows Kiana has been educated on the efficacy and safety of
breastfeeding while taking Subutex, but she also recognizes the importance of
reinforcement and conveying consistent messages. Steph provides her with
reassurance, validation, and offers to bring in one of the lactation consultants for
ongoing breastfeeding support.
At the end of rounds, the team asks Kiana if she has any other questions. Kiana
replies, “Is it okay to hold him?” Robert picks William up out of his hospital crib and
hands him to Kiana with a warm smile. He says to her, “William is such a lucky boy to
have you as his mom.”
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CHAPTER VI: CONCLUSION
CONCLUDING STATEMENT
The need for an evidence-informed approach like the PARTNER model is evident.
The PARTNER model is the first research-informed, systematically developed practice
model designed to specifically address the unique needs of mothers and babies impacted
by the perinatal opioid epidemic. It is intended to be as comprehensive as possible, but it is
not a finite, independent solution this macro-level problem. There are countless potential
combinations of demographics, risk factors, and comorbidities that could impact the way in
which the PARTNER model is integrated into practice.
Future recommendations include the development of a structured curriculum to
educate providers on each of the elements of the PARTNER model and how to effectively
integrate them into clinical practice. Future recommendations also include both short-term
and longitudinal evaluation of the PARTNER model, with possible areas of focus including
changes in mother/infant bonding, maternal engagement in care, NAS treatment outcomes,
and a length of stay cost/benefit analysis.
Though the efficacy of the PARTNER model has not yet been empirically measured,
it is a clinically valuable and innovative approach that fills a deep, destructive gap in
current practice in working with mothers and infants impacted by perinatal opioid use
disorders. The value and impact of early attachment bonding cannot be underestimated.
Early attachment bonding creates a pathway for the way in which individuals engage in
human relationships across the lifespan. Continuing the current practices of alienating,
ostracizing, and stigmatizing pregnant and postpartum women with opioid use disorders
will only perpetuate this cycle of separation, disconnection, and fear.
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By integrating the PARTNER model into the standard of care, healthcare providers can help
mothers and infants, like Kiana and William, by working toward breaking down the
socially-created barriers of stigma and fear that interfere with early attachment bonding,
an essential aspect of human development that deserves to be regarded as a basic human
right.
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